Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.1.1.354 - [histone H3]-lysine4 N-trimethyltransferase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acquired Immunodeficiency Syndrome
A magnetic compass aids monarch butterfly migration.
AIDS and volunteer associations: perspectives on social and individual change.
Diagnostic aids: the Surgical Sieve revisited.
The elephant from the other side of silence (or HIV news from four compass points). XV International AIDS Conference, Bangkok, 11-16 July 2004.
[Remarks on the paper: present means of lokalising intra-ocular foreign bodies, by M. Severin (author's transl)]
Acute Coronary Syndrome
Rivaroxaban in Acute Coronary Syndromes: We Have a Compass and an Atlas, But Where Are We Headed?
[Antithrombotic therapy after acute coronary syndromes: is it possible to identify the PEGASUS and COMPASS patient?]
Adamantinoma
Comprehensive Molecular Characterization of Adamantinoma and OFD-like Adamantinoma Bone Tumors.
Adenocarcinoma
A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer.
Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target.
Feasibility and Safety of Transhiatal Approach and D2 Total Gastrectomy after Neoadjuvant Chemotherapy for Adenocarcinoma of the Esophago-Gastric Junction: A Subset Analysis of the COMPASS Trial.
Genetic characteristics of gastric-type mucinous carcinoma of the uterine cervix.
Histone Methyltransferases Useful in Gastric Cancer Research.
Integrative molecular characterization of Chinese prostate cancer specimens.
KMT2C Mutations in Diffuse-Type Gastric Adenocarcinoma Promote Epithelial-to-Mesenchymal Transition.
KMT2D deficiency enhances the anti-cancer activity of L48H37 in pancreatic ductal adenocarcinoma.
Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study.
Reduced Expression of Histone Methyltransferases KMT2C and KMT2D Correlates with Improved Outcome in Pancreatic Ductal Adenocarcinoma.
SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.
Thymic adenocarcinoma accompanied by type A thymoma and pulmonary minimally invasive adenocarcinoma and harboring distinct gene alterations: A case report.
Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report.
Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma.
Adenocarcinoma of Lung
Comprehensive analysis of age-related somatic mutation profiles in Chinese young lung adenocarcinoma patients.
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
Epigenetic Role of Histone Lysine Methyltransferase and Demethylase on the Expression of Transcription Factors Associated with the Epithelial-to-Mesenchymal Transition of Lung Adenocarcinoma Metastasis to the Brain.
H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma.
Hit identification of SMYD3 enzyme inhibitors using structure-based pharmacophore modeling.
SMYD2 promotes tumorigenesis and metastasis of lung adenocarcinoma through RPS7.
SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.
Adenoma
miR-142-3p down-regulation contributes to thyroid follicular tumorigenesis by targeting ASH1L and MLL1.
Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study.
Adenomatous Polyposis Coli
SMYD2 suppresses APC2 expression to activate the Wnt/?-catenin pathway and promotes epithelial-mesenchymal transition in colorectal cancer.
Agammaglobulinemia
Defects of B-cell terminal differentiation in patients with type-1 Kabuki syndrome.
Alzheimer Disease
Adjusting the compass: new insights into the role of angiogenesis in Alzheimer's disease.
COMPASS: A computational model to predict changes in MMSE scores 24-months after initial assessment of Alzheimer's disease.
Dominantly inherited Alzheimer's disease: a compass for drug development.
Amebiasis
[Candida and amoebiasis acquired in tropical and subtropical climatic zones]
Anemia, Aplastic
A Patient with Kabuki Syndrome Mutation Presenting with Very Severe Aplastic Anemia.
Anemia, Hemolytic, Autoimmune
Autoimmune Cytopenias in Chronic Lymphocytic Leukemia: Focus on Molecular Aspects.
Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease.
Anosmia
Bilateral participation of the hippocampus in familiar landmark navigation by homing pigeons.
Anus, Imperforate
CHARGE and Kabuki syndromes: A phenotypic and molecular link.
Aortic Aneurysm, Abdominal
Replication of Newly Identified Genetic Associations Between Abdominal Aortic Aneurysm and SMYD2, LINC00540, PCIF1/MMP9/ZNF335, and ERG.
Asthma
Direct healthcare cost comparison of Fluticasone propionate/Salmeterol vs Budesonide/Formoterol Maintenance And Reliever Therapy for moderate/severe asthma: Results from Thailand.
Direct healthcare costs associated with management of asthma: comparison of two treatment regimens in Indonesia, Thailand and Vietnam.
Astigmatism
[Postoperative astigmatism in senile cataract operation performed with the compass keratome and pre-placed sutures]
Atherosclerosis
Deficiency of histone lysine methyltransferase SETDB2 in hematopoietic cells promotes vascular inflammation and accelerates atherosclerosis.
Mortality benefit in the COMPASS trial: is it related to superior statistical power or better efficacy and safety?
Myocardin-Related Transcription Factor A Mediates LPS-Induced iNOS Transactivation.
Non-vitamin K antagonist oral anticoagulants (NOACs) in the treatment of coronary and peripheral atherosclerosis. Expert Consensus.
[Do the patients with peripheral atherosclerosis need to a medical therapy before the revascularization?]
Atrial Fibrillation
Compass Mapping, Double Potentials, Activation Patterns Can Identify and Track Rotational Activity Sites in the Left Atrium of Humans with Persistent Atrial Fibrillation.
Non-vitamin K antagonist oral anticoagulants beyond atrial fibrillation: what did we learn from COMPASS and COMMANDER-HF?
Rivaroxaban in patients with ischaemic chronic cardiomyopathy and obstructive peripheral arterial disease: rationale for treatment and results.
Atypical Squamous Cells of the Cervix
MoSnt2-dependent deacetylation of histone H3 mediates MoTor-dependent autophagy and plant infection by the rice blast fungus Magnaporthe oryzae.
Autoimmune Diseases
Ash1l and lnc-Smad3 coordinate Smad3 locus accessibility to modulate iTreg polarization and T cell autoimmunity.
Histone methyltransferase ash1l suppresses interleukin-6 production and inflammatory autoimmune diseases by inducing the ubiquitin-editing enzyme a20.
Azoospermia
Novel karyotypes of partial monosomy 21 and partial monosomy 1 and underlying etiology.
PRDM9 gene polymorphism may not be associated with defective spermatogenesis in the Chinese Han population.
Single Nucleotide Polymorphisms in PRDM9 (MEISETZ) in Patients with Nonobstructive Azoospermia.
Two single nucleotide polymorphisms in PRDM9 (MEISETZ) gene may be a genetic risk factor for Japanese patients with azoospermia by meiotic arrest.
Brain Infarction
Correction to: Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy.
Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial.
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy.
Brain Neoplasms
The epigenetic factor Kmt2a/Mll1 regulates neural progenitor proliferation and neuronal and glial differentiation.
Breast Neoplasms
A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers.
Aberrant expression of SETD1A promotes survival and migration of estrogen receptor ?-positive breast cancer cells.
Absent, small or homeotic 2-like protein (ASH2L) enhances the transcription of the estrogen receptor ? gene through GATA-binding protein 3 (GATA3).
Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.
Analysis of Circulating Tumor DNA to Predict Neoadjuvant Therapy Effectiveness and Breast Cancer Recurrence.
Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer.
Breast cancer cell detection and characterization from breast milk-derived cells.
Breast cancer information and support needs for women with intellectual disabilities: a scoping study.
Comprehensive Analysis of Metabolic Genes in Breast Cancer Based on Multi-Omics Data.
Comprehensive Cohort Analysis of Mutational Spectrum in Early Onset Breast Cancer Patients.
Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target.
Correlation between a variable number tandem repeat (VNTR) polymorphism in SMYD3 gene and breast cancer: A genotype-phenotype study.
Cross-talk between CDK4/6 and SMYD2 regulates gene transcription, tubulin methylation, and ciliogenesis.
DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression.
DOT1L histone methyltransferase regulates the expression of BCAT1 and is involved in sphere formation and cell migration of breast cancer cell lines.
DOT1L: a new therapeutic target for aggressive breast cancer.
Dysregulation of AKT Pathway by SMYD2-Mediated Lysine Methylation on PTEN.
Dysregulation of non-histone molecule miR205 and LRG1 post-transcriptional de-regulation by SETD1A in triple negative breast cancer.
Effect of SMYD3 on the microRNA expression profile of MCF-7 breast cancer cells.
Effects of SMYD3 over-expression on cell cycle acceleration and cell proliferation in MDA-MB-231 human breast cancer cells.
Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells.
Enhanced SMYD3 expression is essential for the growth of breast cancer cells.
Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive Breast Cancer.
Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome.
Gene trio signatures as molecular markers to predict response to doxorubicin cyclophosphamide neoadjuvant chemotherapy in breast cancer patients.
Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.
Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells.
In Silico/In Vitro Hit-to-Lead Methodology Yields SMYD3 Inhibitor That Eliminates Unrestrained Proliferation of Breast Carcinoma Cells.
Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer.
Inhibition of histone methyltransferase DOT1L silences ER? gene and blocks proliferation of antiestrogen-resistant breast cancer cells.
KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer.
KMT2C mediates the estrogen dependence of breast cancer through regulation of ER? enhancer function.
LncRNA GAS6-AS1 facilitates the progression of breast cancer by targeting the miR-324-3p/SETD1A axis to activate the PI3K/AKT pathway.
Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.
Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells.
PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression.
PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.
PI3K Signaling Regulates ER Activity via KMT2D in ER(+) Breast Cancer.
Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization.
Regulation of estrogen receptor ? by histone methyltransferase SMYD2-mediated protein methylation.
Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
Regulation of IL-20 Expression by Estradiol through KMT2B-Mediated Epigenetic Modification.
Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription.
SET and MYND domain-containing protein 3 inhibits tumor cell sensitivity to cisplatin.
SET and MYND domain-containing protein 3 is overexpressed in human glioma and contributes to tumorigenicity.
SETD1A protects from senescence through regulation of the mitotic gene expression program.
SETDB-1: A Potential Epigenetic Regulator in Breast Cancer Metastasis.
SMYD3 promotes the epithelial-mesenchymal transition in breast cancer.
SMYD3 tandem repeats polymorphism is not associated with the occurrence and metastasis of hepatocellular carcinoma in a Chinese population.
SMYD3-Mediated H2A.Z.1 Methylation Promotes Cell Cycle and Cancer Proliferation.
Synthesis and biological activity of selenopsammaplin A and its analogues as antitumor agents with DOT1L inhibitory activity.
Tackling Resistance to PI3K Inhibition by Targeting the Epigenome.
Targeting Histone Methyltransferase DOT1L by a Novel Psammaplin A Analog Inhibits Growth and Metastasis of Triple-Negative Breast Cancer.
Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality.
The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3.
The plasma peptides of breast versus ovarian cancer.
Variable number of tandem repeats polymorphism in the SMYD3 promoter region and the risk of familial breast cancer.
Bronchitis, Chronic
Investigation of the Clinical, Radiological and Biological Factors Associated with Disease Progression, Phenotypes and Endotypes of COPD in China (COMPASS): study design, protocol and rationale.
Burkitt Lymphoma
Burkitt lymphoma in a patient with Kabuki syndrome carrying a novel KMT2D mutation.
Hijacking a key chromatin modulator creates epigenetic vulnerability for MYC-driven cancer.
Role of Dot1L and H3K79 methylation in regulating somatic hypermutation of immunoglobulin genes.
Candidiasis, Invasive
Candida albicans SET1 encodes a histone 3 lysine 4 methyltransferase that contributes to the pathogenesis of invasive candidiasis.
Carcinogenesis
A conserved interaction between the SDI domain of Bre2 and the Dpy-30 domain of Sdc1 is required for histone methylation and gene expression.
A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.
A virome-wide clonal integration analysis platform for discovering cancer viral etiology.
Analysis of SET and MYND Domain-Containing Protein 3 (SMYD3) Expression in Gallbladder Cancer: a Pilot Study.
Association of the variable number of tandem repeats polymorphism in the promoter region of the SMYD3 gene with risk of esophageal squamous cell carcinoma in relation to tobacco smoking.
C-terminal domain of SMYD3 serves as a unique HSP90-regulated motif in oncogenesis.
Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors.
Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer.
Comprehensive Molecular Characterization of Adamantinoma and OFD-like Adamantinoma Bone Tumors.
Computer-aided screening for suppressor of variegation 4-20 homolog 1 inhibitors and their preliminary activity validation in human osteosarcoma.
Crystal structures of histone and p53 methyltransferase SmyD2 reveal a conformational flexibility of the autoinhibitory C-terminal domain.
Depletion of H3K79 methyltransferase Dot1L promotes cell invasion and cancer stem-like cell property in ovarian cancer.
Discovery of a chemical probe for PRDM9.
Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis.
Downregulation of KMT2D suppresses proliferation and induces apoptosis of gastric cancer.
Downregulation of MMSET impairs breast cancer proliferation and metastasis through inhibiting Wnt/?-catenin signaling.
Enhanced SMYD3 expression is essential for the growth of breast cancer cells.
Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma.
Euchromatic histone lysine methyltransferase 1 regulates cancer development in human gastric cancer by regulating E-cadherin.
Exome sequencing identifies novel mutation signatures of UV radiation and trichostatin A in primary human keratinocytes.
Exploration of the Substrate Preference of Lysine Methyltransferase SMYD3 by Molecular Dynamics Simulations.
Genetic and Epigenetic of Medullary Thyroid Cancer
Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone.
Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.
Hepatitis B virus X protein upregulates expression of SMYD3 and C-MYC in HepG2 cells.
High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.
Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression.
Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway.
Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4.
Histone Methyltransferase SETD1A Induces Epithelial-Mesenchymal Transition to Promote Invasion and Metastasis Through Epigenetic Reprogramming of Snail in Gastric Cancer.
In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype.
Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.
Integrated Molecular Analysis of Papillary Renal Cell Carcinoma and Precursor Lesions Unfolds Evolutionary Process from Kidney Progenitor-Like Cells.
Kmt2a cooperates with menin to suppress tumorigenesis in mouse pancreatic islets.
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
Mechanism of the Conformational Change of the Protein Methyltransferase SMYD3: A Molecular Dynamics Simulation Study.
miR-142-3p down-regulation contributes to thyroid follicular tumorigenesis by targeting ASH1L and MLL1.
miRNA-584-3p inhibits gastric cancer progression by repressing Yin Yang 1- facilitated MMP-14 expression.
Multiple myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity.
Network analyses elucidate the role of SMYD3 in esophageal squamous cell carcinoma.
Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells.
Playing on the Dark Side: SMYD3 Acts as a Cancer Genome Keeper in Gastrointestinal Malignancies.
Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization.
Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy.
Role of the SMYD3 histone methyltransferase in tumorigenesis: local or global effects?
SET and MYND domain-containing protein 3 is overexpressed in human glioma and contributes to tumorigenicity.
SETD1A modulates cell cycle progression through a miRNA network that regulates p53 target genes.
Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration.
SMYD2 promotes tumorigenesis and metastasis of lung adenocarcinoma through RPS7.
SMYD2-dependent HSP90 methylation promotes cancer cell proliferation by regulating the chaperone complex formation.
SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.
SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.
Smyd3 Is a Transcriptional Potentiator of Multiple Cancer-Promoting Genes and Required for Liver and Colon Cancer Development.
SMYD3 Is an Oncogene Required for Liver and Colon Tumorigenesis.
Smyd3 is required for the development of cardiac and skeletal muscle in zebrafish.
SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.
SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma.
SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters.
SMYD3: An Oncogenic Driver Targeting Epigenetic Regulation and Signaling Pathways.
Smyd5 plays pivotal roles in both primitive and definitive hematopoiesis during zebrafish embryogenesis.
Substituted purine and 7-deazapurine compounds as modulators of epigenetic enzymes: a patent evaluation (WO2012075381).
Targeting epigenetic regulators for cancer therapy.
Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality.
The histone methyltransferase DOT1L promotes neuroblastoma by regulating gene transcription.
The Histone Methyltransferase SMYD2 Methylates PARP1 and Promotes Poly(ADP-ribosyl)ation Activity in Cancer Cells.
The Lysine Methylase SMYD3 Modulates Mesendodermal Commitment during Development.
The nuclear-cytoplasmic trafficking of a chromatin-modifying and remodelling protein (KMT2C), in osteosarcoma.
Thymic adenocarcinoma accompanied by type A thymoma and pulmonary minimally invasive adenocarcinoma and harboring distinct gene alterations: A case report.
Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma.
UTX Mutations in Human Cancer.
Whole-exome analysis in osteosarcoma to identify a personalized therapy.
Whole-Exome Sequencing Reveals Frequent Mutations in Chromatin Remodeling Genes in Mammary and Extramammary Paget's Diseases.
[Induction of SMYD3 by hepatitis B virus X gene in HepG2 cells.]
Carcinoma
Acquired Cystic Kidney Disease-associated Renal Cell Carcinoma (ACKD-RCC) Harbor Recurrent Mutations in KMT2C and TSC2 Genes.
Association of the variable number of tandem repeats polymorphism in the promoter region of the SMYD3 gene with risk of esophageal squamous cell carcinoma in relation to tobacco smoking.
ATM Signaling Pathway Is Implicated in the SMYD3-mediated Proliferation and Migration of Gastric Cancer Cells.
Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants.
Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target.
Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma.
Effect of the downregulation of SMYD3 expression by RNAi on RIZ1 expression and proliferation of esophageal squamous cell carcinoma.
Expression and clinical significance of COMPASS family of histone methyltransferases in clear cell renal cell carcinoma.
Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.
Genomic Analyses of Metaplastic or Sarcomatoid Carcinomas From Different Organs Revealed Frequent Mutations in KMT2D.
Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.
Investigation of Genetic Mutations in High-risk and Low-risk Basal Cell Carcinoma in a Non-Caucasian Population by Whole Exome Sequencing.
KMT2A regulates cervical cancer cell growth through targeting VDAC1.
Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF.
Knockdown of SMYD3 by RNA interference inhibits cervical carcinoma cell growth and invasion in vitro.
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
Merkel Cell Polyomavirus in Merkel Cell Carcinoma: Integration Sites and Involvement of the KMT2D Tumor Suppressor Gene.
miR-142-3p down-regulation contributes to thyroid follicular tumorigenesis by targeting ASH1L and MLL1.
Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations.
Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas.
Network analyses elucidate the role of SMYD3 in esophageal squamous cell carcinoma.
Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous-cell carcinoma.
Quantitative Profiling of the Activity of Protein Lysine Methyltransferase SMYD2 Using SILAC-Based Proteomics.
RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation.
SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12.
SETD2, GIGYF2, FGFR3, BCR, KMT2C, and TSC2 as candidate genes for differentiating multilocular cystic renal neoplasm of low malignant potential from clear cell renal cell carcinoma with cystic change.
SMYD2 overexpression is associated with tumor cell proliferation and a worse outcome in human papillomavirus-unrelated nonmultiple head and neck carcinomas.
SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.
SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma.
SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.
SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration and invasion in esophageal squamous cell carcinoma.
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
The histone demethylase UTX/KDM6A in cancer: Progress and puzzles.
The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells.
Upregulation of histone methyltransferase, DOT1L by matrix hyaluronan promotes MicroRNA-10 expression leading to tumor cell invasion and chemoresistance in cancer stem cells from head and neck squamous cell carcinoma.
VHL-HIF-2? axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR.
Whole Exome Sequencing of Ulcerative Colitis-associated Colorectal Cancer Based on Novel Somatic Mutations Identified in Chinese Patients.
Carcinoma in Situ
Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
Carcinoma, Adenoid Cystic
Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.
Carcinoma, Adenosquamous
Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report.
Carcinoma, Basal Cell
Investigation of Genetic Mutations in High-risk and Low-risk Basal Cell Carcinoma in a Non-Caucasian Population by Whole Exome Sequencing.
Carcinoma, Hepatocellular
A Novel lncRNA IHS Promotes Tumor Proliferation and Metastasis in HCC by Regulating the ERK- and AKT/GSK-3?-Signaling Pathways.
A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers.
Amplification of SMYD3 promotes tumorigenicity and intrahepatic metastasis of hepatocellular carcinoma via upregulation of CDK2 and MMP2.
ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma.
C/EBPalphap30 plays transcriptional regulatory roles distinct from C/EBPalphap42.
Correction: SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters.
Diffuse Adenomatosis and Hepatocellular Carcinoma Treated with Liver Transplantation in an Adolescent Female with Kabuki Syndrome with a Novel KMT2D Gene Mutation.
Divergent viral presentation among human tumors and adjacent normal tissues.
Enhanced SMYD3 expression is essential for the growth of breast cancer cells.
Hepatitis B virus X protein regulates the mEZH2 promoter via the E2F1-binding site in AML12 cells.
Hepatitis B virus X protein upregulates expression of SMYD3 and C-MYC in HepG2 cells.
High?level SETD1B gene expression is associated with unfavorable prognosis in hepatocellular carcinoma.
Histone H3K4 trimethylation by MLL3 as part of ASCOM complex is critical for NR activation of bile acid transporter genes and is downregulated in cholestasis.
Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma.
In Silico/In Vitro Hit-to-Lead Methodology Yields SMYD3 Inhibitor That Eliminates Unrestrained Proliferation of Breast Carcinoma Cells.
MiR-346 suppresses cell proliferation through SMYD3 dependent approach in hepatocellular carcinoma.
Overexpression of SMYD3 Is Predictive of Unfavorable Prognosis in Hepatocellular Carcinoma.
Positive Expression of SMYD2 is Associated with Poor Prognosis in Patients with Primary Hepatocellular Carcinoma.
SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration.
SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.
SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters.
SMYD3 tandem repeats polymorphism is not associated with the occurrence and metastasis of hepatocellular carcinoma in a Chinese population.
Targeting Smyd3 by next-generation antisense oligonucleotides suppresses liver tumor growth.
The SMYD3 VNTR 3/3 polymorphism confers an increased risk and poor prognosis of hepatocellular carcinoma in a Chinese population.
Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma.
ZNF479 downregulates metallothionein-1 expression by regulating ASH2L and DNMT1 in hepatocellular carcinoma.
[Experimental research of therapeutic effect on hepatocellular carcinoma of targeting SMYD3 gene inhibition by RNA interference]
[Induction of SMYD3 by hepatitis B virus X gene in HepG2 cells.]
[Inhibition of SMYD3 gene expression by RNA interference induces apoptosis in human hepatocellular carcinoma cell line HepG2]
[Suppression of SMYD3 expression in HepG2 cell by shRNA interference.]
Carcinoma, Merkel Cell
Merkel Cell Polyomavirus in Merkel Cell Carcinoma: Integration Sites and Involvement of the KMT2D Tumor Suppressor Gene.
Carcinoma, Non-Small-Cell Lung
Inhibition of SMYD2 Sensitized Cisplatin to Resistant Cells in NSCLC Through Activating p53 Pathway.
KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer.
The H3K4 methyltransferase SETD1A is required for proliferation of non-small cell lung cancer cells by promoting S-phase progression.
Carcinoma, Ovarian Epithelial
SMYD3 promotes epithelial ovarian cancer metastasis by down-regulating p53 protein stability and promoting p53 ubiquitination.
Carcinoma, Renal Cell
Acquired Cystic Kidney Disease-associated Renal Cell Carcinoma (ACKD-RCC) Harbor Recurrent Mutations in KMT2C and TSC2 Genes.
Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma.
Expression and clinical significance of COMPASS family of histone methyltransferases in clear cell renal cell carcinoma.
Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.
SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12.
SETD2, GIGYF2, FGFR3, BCR, KMT2C, and TSC2 as candidate genes for differentiating multilocular cystic renal neoplasm of low malignant potential from clear cell renal cell carcinoma with cystic change.
VHL-HIF-2? axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR.
Carcinoma, Squamous Cell
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants.
KMT2A regulates cervical cancer cell growth through targeting VDAC1.
Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations.
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Upregulation of histone methyltransferase, DOT1L by matrix hyaluronan promotes MicroRNA-10 expression leading to tumor cell invasion and chemoresistance in cancer stem cells from head and neck squamous cell carcinoma.
Cardiomegaly
A crosstalk between chromatin remodeling and histone H3K4 methyltransferase complexes in endothelial cells regulates angiotensin II-induced cardiac hypertrophy.
LncRNA NEAT1 promotes cardiac hypertrophy through microRNA-19a-3p/SMYD2 axis.
The chromatin-binding protein Smyd1 restricts adult mammalian heart growth.
Cardiomyopathy, Dilated
TALEN-Mediated FLAG-Tagging of Endogenous Histone Methyltransferase DOT1L.
Targeted disruption of the histone lysine 79 methyltransferase Dot1L in nephron progenitors causes congenital renal dysplasia.
Cardiomyopathy, Hypertrophic
A de novo mutation of SMYD1 (p.F272L) is responsible for hypertrophic cardiomyopathy in a Chinese patient.
Cardiovascular Diseases
A critical analysis of the COMPASS trial with respect to benefit-risk assessment using the numbers needed to treat: Applicability and relevance in Indian patients with stable cardiovascular disease.
Crystal structure of cardiac specific histone methyltransferase SmyD1 reveals unusual active site architecture.
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial.
Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease.
Histone methyltransferase SMYD2: ubiquitous regulator of disease.
Large-Scale Implementation of Collaborative Care Management for Depression and Diabetes and/or Cardiovascular Disease.
Review of article: Rivaroxaban with or without aspirin in stable cardiovascular disease. Eikelboom JW, Connolly SJ, Bosch J, et al. for the COMPASS investigators.
Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial.
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial.
Sustainable care coordination: a qualitative study of primary care provider, administrator, and insurer perspectives.
The COMPASS initiative: description of a nationwide collaborative approach to the care of patients with depression and diabetes and/or cardiovascular disease.
The Global Burden of Cardiovascular Diseases and Risks: A Compass for Global Action.
Usefulness of Coronary Artery Calcium to Identify Adults of Sufficiently High Risk for Atherothrombotic Cardiovascular Events to Consider Low-Dose Rivaroxaban Thromboprophylaxis (from MESA).
[Atherosclerotic Cardiovascular Diseases and Type 2 Diabetes Mellitus - new Developments in the Treatment].
[Combined Antithrombotic Therapy in Patients with a Stable Atherosclerotic Cardiovascular Diseases: What Direction did COMPASS Show?]
Carotid Artery Diseases
Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial.
Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective.
Cataract
Circular RNA circ KMT2E is up-regulated in diabetic cataract lenses and is associated with miR-204-5p sponge function.
Corneal Endothelial Cell Density and Morphology After Phacoemulsification in Patients With Primary Open-Angle Glaucoma and Cataracts: 2-Year Results of a Randomized Multicenter Trial.
Safety profile of minimally invasive glaucoma surgery.
Suprachoroidal shunts.
Two-Year COMPASS Trial Results: Supraciliary Microstenting with Phacoemulsification in Patients with Open-Angle Glaucoma and Cataracts.
[Considerations on the opening of the anterior chamber in the cataract operation. Compass keratome]
[Postoperative astigmatism in senile cataract operation performed with the compass keratome and pre-placed sutures]
Central Nervous System Diseases
Histone lysine methyltransferase SETDB1 as a novel target for central nervous system diseases.
Cerebellar Ataxia
Novel KMT2B mutation causes cerebellar ataxia: Expanding the clinical phenotype.
Chagas Disease
Antiproliferative effects of delta 24(25) sterol methyl transferase inhibitors on Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies.
CHARGE Syndrome
CHARGE and Kabuki syndromes: A phenotypic and molecular link.
KMT2D p.Gln3575His segregating in a family with autosomal dominant choanal atresia strengthens the Kabuki/CHARGE connection.
Neuroimaging in Kabuki syndrome and another KMT2D-related disorder.
Choanal Atresia
KMT2D p.Gln3575His segregating in a family with autosomal dominant choanal atresia strengthens the Kabuki/CHARGE connection.
Phenotypic expansion of KMT2D-related disorder: Beyond Kabuki syndrome.
Cholangiocarcinoma
Epigenetic regulation of miR-124 by Hepatitis C Virus core protein promotes migration and invasion of intrahepatic cholangiocarcinoma cells by targeting SMYD3.
Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells.
Cholelithiasis
Analysis of SET and MYND Domain-Containing Protein 3 (SMYD3) Expression in Gallbladder Cancer: a Pilot Study.
Cleft Palate
The KMT2D Kabuki syndrome histone methylase controls neural crest cell differentiation and facial morphology.
Colitis
Ash1l and lnc-Smad3 coordinate Smad3 locus accessibility to modulate iTreg polarization and T cell autoimmunity.
Colonic Neoplasms
CBP mediated DOT1L acetylation confers DOT1L stability and promotes cancer metastasis.
NSD2 promotes osteosarcoma cell proliferation and metastasis by inhibiting E-cadherin expression.
Overexpression of histone deacetylases in cancer cells is controlled by interplay of transcription factors and epigenetic modulators.
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Regulation of Wnt signaling target gene expression by the histone methyltransferase DOT1L.
SMYD2 facilitates cancer cell malignancy and xenograft tumor development through ERBB2-mediated FUT4 expression in colon cancer.
Smyd3 Is a Transcriptional Potentiator of Multiple Cancer-Promoting Genes and Required for Liver and Colon Cancer Development.
SMYD3 promotes colon adenocarcinoma (COAD) progression by mediating cell proliferation and apoptosis.
WDR5 supports colon cancer cells by promoting methylation of H3K4 and suppressing DNA damage.
Colorectal Neoplasms
A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.
A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers.
CBP mediated DOT1L acetylation confers DOT1L stability and promotes cancer metastasis.
Copy number analysis of whole-genome data using BIC-seq2 and its application to detection of cancer susceptibility variants.
Enhanced SMYD3 expression is essential for the growth of breast cancer cells.
Frameshift mutation of a histone methylation-related gene SETD1B and its regional heterogeneity in gastric and colorectal cancers with high microsatellite instability.
IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L.
KMT2A histone methyltransferase contributes to colorectal cancer development by promoting cathepsin Z transcriptional activation.
miR-133b suppresses colorectal cancer cell stemness and chemoresistance by targeting methyltransferase DOT1L.
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Prognosis model of colorectal cancer patients based on NOTCH3, KMT2C, and CREBBP mutations.
Prognostic significance of stromal SMYD3 expression in colorectal cancer of TNM stage I-III.
Restoration of KMT2C/MLL3 in human colorectal cancer cells reinforces genome-wide H3K4me1 profiles and influences cell growth and gene expression.
Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer.
SMYD2 suppresses APC2 expression to activate the Wnt/?-catenin pathway and promotes epithelial-mesenchymal transition in colorectal cancer.
SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.
SMYD3 promoter hypomethylation is associated with the risk of colorectal cancer.
SMYD3 tandem repeats polymorphism is not associated with the occurrence and metastasis of hepatocellular carcinoma in a Chinese population.
The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness.
The leukemia-associated Mllt10/Af10-Dot1l are Tcf4/?-catenin coactivators essential for intestinal homeostasis.
Uncommon somatic mutations in metastatic NUT midline carcinoma.
Communicable Diseases
Correction to: PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside.
PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside.
Confusion
Looking for the compass in a case of developmental topographical disorientation: a behavioral and neuroimaging study.
The quantum needle of the avian magnetic compass.
The role of ethics in science: a systematic literature review from the first wave of COVID-19.
Congenital Abnormalities
Distal Tibial Tuberosity Focal Dome Osteotomy Combined With Intra-Articular Condylar Osteotomy (Focal Dome Condylar Osteotomy) for Medial Osteoarthritis of the Knee Joint.
Tooth agenesis and orofacial clefting: genetic brothers in arms?
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Identification of KMT2D and KDM6A variants by targeted sequencing from patients with Kabuki syndrome and other congenital disorders.
Contracture
Chronic flexion contracture of proximal interphalangeal joint treated with the compass hinge external fixator. A consecutive series of 27 cases.
Compass elbow hinge: short-term results in five adolescents.
Compass hinge fixator for acute and chronic instability of the elbow.
The Compass Elbow Hinge: indications and initial results.
Corneal Injuries
Dot1l Aggravates Keratitis Induced by Herpes Simplex Virus Type 1 in Mice via p38 MAPK-Mediated Oxidative Stress.
Corneal Opacity
Bilateral Congenital Corneal Opacities as an Early-Onset Ocular Feature of Kabuki Syndrome.
Coronary Artery Disease
A Blood Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Non-Diabetic Patients Referred for Myocardial Perfusion Imaging: The COMPASS Study.
Assessment of patients with coronary artery disease who may benefit from the use of rivaroxaban in the real world: implementation of the COMPASS trial criteria in the TERCET registry population.
Balloon angioplasty plus cilostazol administration versus primary stenting of small coronary artery disease: final results of COMPASS.
Biological and analytical stability of a peripheral blood gene expression score for obstructive coronary artery disease in the PREDICT and COMPASS studies.
Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry.
Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial.
COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: insights from the START registry.
Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
External applicability of the COMPASS trial: the Western Denmark Heart Registry.
Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease.
Medical management of stable peripheral artery disease: the COMPASS trial. Perspectives from a vascular standpoint.
Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial.
Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease.
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.
Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
The COMPASS trial: practical considerations for application after coronary artery bypass surgery.
Coronary Disease
Anticoagulation in Atherosclerotic Disease.
Role of rivaroxaban in the prevention of atherosclerotic events.
[Do the patients with peripheral atherosclerosis need to a medical therapy before the revascularization?]
[Health and disease in the Netherlands: the Dutch National Public Health Compass as a source of information]
COVID-19
Care without a compass: Including patients with cancer in COVID-19 studies.
Differences in COVID-19 Vaccine Concerns Among Asian Americans and Pacific Islanders: The COMPASS Survey.
Examining the impact of the early stages of the COVID-19 pandemic period on youth cannabis use: adjusted annual changes between the pre-COVID and initial COVID-lockdown waves of the COMPASS study.
Motivating Developers to Use Interoperable Standards for Data in Pandemic Health Apps.
Reading the Compass - Procedural Sedation and COVID-19.
Single-Cell RNA Sequencing Analysis of the Immunometabolic Rewiring and Immunopathogenesis of Coronavirus Disease 2019.
The 2020 APSA Robert E. Gross Lecture: Pediatric Surgery, COVID 19, and the moral compass.
The role of ethics in science: a systematic literature review from the first wave of COVID-19.
Value-based medicine, a compass to guide healthcare decisions in the COVID-19 aftermath.
Craniosynostoses
Expression pattern of Kmt2d in murine craniofacial tissues.
On the significance of craniosynostosis in a case of Kabuki syndrome with a concomitant KMT2D mutation and 3.2?Mbp de novo 10q22.3q23.1 deletion.
Cysts
Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.
Polycystic kidney disease: SMYD2 is a novel epigenetic regulator of cyst growth.
Single-cell RNA sequencing reveals regulation of fetal ovary development in the monkey (Macaca fascicularis).
Cytomegalovirus Infections
Three de novo variants in KMT2A (MLL) identified by whole exome sequencing in patients with Wiedemann-Steiner syndrome.
Dandy-Walker Syndrome
Cancer Management in Kabuki Syndrome: The First Case of Wilms Tumor and a Literature Review.
Dementia
CoMPASs: IOn programme (Care Of Memory Problems in Advanced Stages of dementia: Improving Our Knowledge): protocol for a mixed methods study.
The battle of Alzheimer's Disease - the beginning of the future Unleashing the potential of academic discoveries.
Dermatitis
Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer.
Dermatitis, Allergic Contact
Benign summer light eruption and polymorphic light eruption: genetic and functional studies suggest that a revised nomenclature is required.
Diabetes Mellitus
Efficacy and Safety of Long-Term Antithrombotic Strategies in Patients With Chronic Coronary Syndrome: A Network Meta-analysis of Randomized Controlled Trials.
Impact of structured self-monitoring of blood glucose on the quality of life of insulin-treated Chinese patients with type 2 diabetes mellitus: Results from the COMPASS study.
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial.
[New possibilities of antithrombotic therapy improving prognosis in patients with stenosing atherosclerosis of carotid arteries].
Diabetes Mellitus, Type 2
Combination of Composite Autonomic Symptom Score 31 and Heart Rate Variability for Diagnosis of Cardiovascular Autonomic Neuropathy in People with Type 2 Diabetes.
Glycemic control and self-monitoring of blood glucose in Chinese patients with type 2 diabetes on insulin: Baseline results from the COMPASS study.
Impact of structured self-monitoring of blood glucose on the quality of life of insulin-treated Chinese patients with type 2 diabetes mellitus: Results from the COMPASS study.
Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in mice.
Diabetic Neuropathies
The diagnostic usefulness of the combined COMPASS 31 questionnaire and electrochemical skin conductance for diabetic cardiovascular autonomic neuropathy and diabetic polyneuropathy.
Validation of the Composite Autonomic Symptom Score 31 (COMPASS 31) for the assessment of symptoms of autonomic neuropathy in people with diabetes.
Diverticulum
[The aorto-mesenteric compass in the etiopathogenesis of the duodenal diverticulum caused by pressure]
Down Syndrome
Outcome of Childhood Acute Megakaryoblastic Leukemia: Children's Cancer Hospital Egypt 57357 Experience.
The genetic landscape of paediatric de novo acute myeloid leukaemia as defined by single nucleotide polymorphism array and exon sequencing of 100 candidate genes.
Variation in the Zinc Finger of PRDM9 is Associated with the Absence of Recombination along Nondisjoined Chromosomes 21 of Maternal Origin.
Dyskinesias
Emerging Monogenic Complex Hyperkinetic Disorders.
Dyspnea
Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study.
Dystonia
A novel, in-frame KMT2B deletion in a patient with apparently isolated, generalized dystonia.
An atypical case of early-onset dystonia with a novel missense variant in KMT2B.
An inherited KMT2B duplication variant in a Chinese family with dystonia and/or development delay.
Childhood-onset dystonia-causing KMT2B variants result in a distinctive genomic hypermethylation profile.
Clinical phenotypes, genotypes and treatment in Chinese dystonia patients with KMT2B variants.
Correction to: Novel mutations in KMT2B offer pathophysiological insights on childhood-onset progressive dystonia.
Corrigendum: Mutations in the histone methyltransferase gene KMT2B cause complex early-onset dystonia.
De-novo KMT2B mutation in a consanguineous family: 15-Year follow-up of an Afghan dystonia patient.
Dystonia.
Emerging Monogenic Complex Hyperkinetic Disorders.
Exome sequencing in paediatric patients with movement disorders.
Frequency and phenotypic spectrum of KMT2B dystonia in childhood: A single-center cohort study.
Generalized dystonia associated with mutation in the histone methyltransferase gene KMT2B (DYT28) and white matter abnormalities.
Genotype-Phenotype Relations for Isolated Dystonia Genes: MDSGene Systematic Review.
Haploinsufficiency of KMT2B, Encoding the Lysine-Specific Histone Methyltransferase 2B, Results in Early-Onset Generalized Dystonia.
Identification of a novel de novo KMT2B variant in a Greek dystonia patient via exome sequencing genotype-phenotype correlations of all published cases.
Identification of Novel KMT2B Variants in Chinese Dystonia Patients via Whole-Exome Sequencing.
KMT2B and Neuronal Transdifferentiation: Bridging Basic Chromatin Mechanisms to Disease Actionability.
KMT2B Is Selectively Required for Neuronal Transdifferentiation, and Its Loss Exposes Dystonia Candidate Genes.
KMT2B rare missense variants in generalized dystonia.
KMT2B-related disorders: expansion of the phenotypic spectrum and long-term efficacy of deep brain stimulation.
KMT2B: A new twist in dystonia genetics.
Mutations in the histone methyltransferase gene KMT2B cause complex early-onset dystonia.
Novel KMT2B mutation causes cerebellar ataxia: Expanding the clinical phenotype.
Novel mutations in KMT2B offer pathophysiological insights into childhood-onset progressive dystonia.
Radiofrequency ablation for DYT-28 dystonia: short term follow-up of three adult cases.
Review of the phenotype of early-onset generalised progressive dystonia due to mutations in KMT2B.
Successful Pallidal Stimulation in a Patient with KMT2B-Related Dystonia.
Update on KMT2B-Related Dystonia.
Update on the Genetics of Dystonia.
Eczema
Benign summer light eruption and polymorphic light eruption: genetic and functional studies suggest that a revised nomenclature is required.
Endocardial Fibroelastosis
Three de novo variants in KMT2A (MLL) identified by whole exome sequencing in patients with Wiedemann-Steiner syndrome.
Endometrial Neoplasms
ASH2L is involved in promotion of endometrial cancer progression via upregulation of PAX2 transcription.
Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma.
Endometriosis
A compass for understanding endometriosis.
Malignant phyllodes tumour of the breast mimicking endometriosis.
Eosinophilia
A novel deletion mutation in KMT2A identified in a child with ID/DD and blood eosinophilia.
Ependymoma
Spinal ependymoma in a patient with Kabuki syndrome: a case report.
Epilepsies, Partial
Facial Dysmorphisms, Macrodontia, Focal Epilepsy, and Thinning of the Corpus Callosum: A Rare Mild Form of Kabuki Syndrome.
Epilepsy
A novel de novo frameshift variant in SETD1B causes epilepsy.
An atypical 12q24.31 microdeletion implicates six genes including a histone demethylase KDM2B and a histone methyltransferase SETD1B in syndromic intellectual disability.
Characteristics of epilepsy in patients with Kabuki syndrome with KMT2D mutations.
Congenital immunodeficiency in an individual with Wiedemann-Steiner syndrome due to a novel missense mutation in KMT2A.
De Novo and Inherited SETD1A Variants in Early-onset Epilepsy.
De novo variants in SETD1B are associated with intellectual disability, epilepsy and autism.
De novo variants in SETD1B cause intellectual disability, autism spectrum disorder, and epilepsy with myoclonic absences.
Delineating the molecular and phenotypic spectrum of the SETD1B-related syndrome.
Heterozygous Variants in KMT2E Cause a Spectrum of Neurodevelopmental Disorders and Epilepsy.
Identification of De Novo DNMT3A Mutations That Cause West Syndrome by Using Whole-Exome Sequencing.
ODLURO syndrome: personal experience and review of the literature.
SETD1B-associated neurodevelopmental disorder.
Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study).
Esophageal Neoplasms
Associations of the variable number of tandem repeats polymorphism in the SMYD3 gene with risk and prognosis of esophageal cancer: a case-control study.
Esophageal Squamous Cell Carcinoma
Association of the variable number of tandem repeats polymorphism in the promoter region of the SMYD3 gene with risk of esophageal squamous cell carcinoma in relation to tobacco smoking.
Effect of the downregulation of SMYD3 expression by RNAi on RIZ1 expression and proliferation of esophageal squamous cell carcinoma.
Network analyses elucidate the role of SMYD3 in esophageal squamous cell carcinoma.
Quantitative Profiling of the Activity of Protein Lysine Methyltransferase SMYD2 Using SILAC-Based Proteomics.
SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration and invasion in esophageal squamous cell carcinoma.
Fanconi Anemia
An uncommon t(9;11)(p24;q22) with monoallelic loss of ATM and KMT2A genes in a child with myelodysplastic syndrome/acute myeloid leukemia who evolved from Fanconi anemia.
Fibromyalgia
Autonomic Dysfunction in Fibromyalgia Assessed by the Composite Autonomic Symptoms Scale (COMPASS).
Clinical Assessment of Autonomic Function in Fibromyalgia by the Refined and Abbreviated Composite Autonomic Symptom Score (COMPASS 31): A Case-Controlled Study.
Heart Rate Variability for Quantification of Autonomic Dysfunction in Fibromyalgia.
HPV vaccination syndrome. A questionnaire-based study.
Fibrosarcoma
Recurrent Fusions Between YAP1 and KMT2A in Morphologically Distinct Neoplasms Within the Spectrum of Low-grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma.
Recurrent YAP1 and KMT2A Gene Rearrangements in a Subset of MUC4-negative Sclerosing Epithelioid Fibrosarcoma.
SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9.
Fracture Dislocation
Management of a proximal interphalangeal joint fracture dislocation with a compass proximal interphalangeal joint hinge and therapy: a case report.
Friedreich Ataxia
HMTase Inhibitors as a Potential Epigenetic-Based Therapeutic Approach for Friedreich's Ataxia.
Gallbladder Neoplasms
Analysis of SET and MYND Domain-Containing Protein 3 (SMYD3) Expression in Gallbladder Cancer: a Pilot Study.
Genetic Diseases, Inborn
An unusual presentation of Kabuki syndrome with orbital cysts, microphthalmia, and cholestasis with bile duct paucity.
Broad neurodevelopmental features and cortical anomalies associated with a novel de novo KMT2A variant in Wiedemann-Steiner syndrome.
Burkitt lymphoma in a patient with Kabuki syndrome carrying a novel KMT2D mutation.
Changes in ocular motility in Kabuki syndrome.
De novo loss-of-function variants of ASH1L are associated with an emergent neurodevelopmental disorder.
Description of the molecular and phenotypic spectrum of Wiedemann-Steiner syndrome in Chinese patients.
On the significance of craniosynostosis in a case of Kabuki syndrome with a concomitant KMT2D mutation and 3.2?Mbp de novo 10q22.3q23.1 deletion.
Ophthalmic manifestations in Kabuki (make-up) syndrome: A single-center pediatric cohort and systematic review of the literature.
Wiedemann-Steiner syndrome with a novel pathogenic variant in KMT2A: a case report.
Glaucoma
Agreement between Compass Fundus Perimeter New Grid and 10-2 Testing Protocols for Detecting Central Visual Field Defects.
Comparing the Performance of Compass Perimetry With Humphrey Field Analyzer in Eyes With Glaucoma.
Comparison of Compass and Humphrey perimeters in detecting glaucomatous defects.
Compass fundus automated perimetry.
Compass: clinical evaluation of a new instrument for the diagnosis of glaucoma.
Intraocular Pressure Following Prerandomization Glaucoma Medication Washout in the HORIZON and COMPASS Trials.
Management of Persistent Hypotony after Supraciliary CyPass® Implantation Using Argon Laser.
Visual Field Endpoints Based on Subgroups of Points May Be Useful in Glaucoma Clinical Trials: A Study With the Humphrey Field Analyzer and Compass Perimeter.
Glaucoma, Open-Angle
Comparison of the structure-function relationship between compass microperimetry and Humphrey field analyser in myopic open-angle glaucoma eyes.
Corneal Endothelial Cell Density and Morphology After Phacoemulsification in Patients With Primary Open-Angle Glaucoma and Cataracts: 2-Year Results of a Randomized Multicenter Trial.
Intraocular Pressure Following Prerandomization Glaucoma Medication Washout in the HORIZON and COMPASS Trials.
Safety and Effectiveness of CyPass Supraciliary Micro-Stent in Primary Open-Angle Glaucoma: Five-Year Results from the COMPASS XT Study.
Two-Year COMPASS Trial Results: Supraciliary Microstenting with Phacoemulsification in Patients with Open-Angle Glaucoma and Cataracts.
Glioblastoma
Epigenetic regulation of NOTCH1 and NOTCH3 by KMT2A inhibits glioma proliferation.
Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
NF1 glioblastoma clonal profiling reveals KMT2B mutations as potential somatic oncogenic events.
Glioma
EGFR promoter exhibits dynamic histone modifications and binding of ASH2L and P300 in human germinal matrix and gliomas.
Epigenetic regulation of NOTCH1 and NOTCH3 by KMT2A inhibits glioma proliferation.
EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients.
Identification of an epigenetic prognostic signature for patients with lower-grade gliomas.
MicroRNA-769-5p Promotes The Growth Of Glioma Cells By Targeting Lysine Methyltransferase 2A.
SET and MYND domain-containing protein 3 is overexpressed in human glioma and contributes to tumorigenicity.
Glucose Intolerance
Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in mice.
Graft vs Host Disease
DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models.
Head and Neck Neoplasms
Radiogenomics in head and neck cancer: correlation of radiomic heterogeneity and somatic mutations in TP53, FAT1 and KMT2D.
Hearing Loss
CHARGE and Kabuki syndromes: A phenotypic and molecular link.
Inhibition of Histone Methyltransferase G9a Attenuates Noise-Induced Cochlear Synaptopathy and Hearing Loss.
[One novel pathologic variation in KMT2D cause Kabuki syndrome with hearing loss as the main phenotype and related research on types of deafness].
Heart Defects, Congenital
Clinical presentation and genetic profiles of Chinese patients with velocardiofacial syndrome in a large referral centre.
COMPASS: A Novel Risk-Adjustment Model for Catheter Ablation in Pediatric and Congenital Heart Disease Patients.
Epigenetic mechanisms in cardiac development and disease.
KMT2D regulates specific programs in heart development via histone H3 lysine 4 di-methylation.
Loss of function of Kmt2d, a gene mutated in Kabuki syndrome, affects heart development in Xenopus laevis.
Prenatal diagnosis of a familial 5p14.3-p14.1 deletion encompassing CDH18, CDH12, PMCHL1, PRDM9 and CDH10 in a fetus with congenital heart disease on prenatal ultrasound.
Heart Diseases
Anticoagulation in Patients with Ischaemic Heart Disease and Peripheral Arterial Disease: Clinical Implications of COMPASS Study.
Democratizing health system data to impact social and environmental health contexts: a novel collaborative community data-sharing model.
Use of direct oral anticoagulant in ischaemic heart disease: the COMPASS study.
[New possibilities of antithrombotic therapy improving prognosis in patients with stenosing atherosclerosis of carotid arteries].
Heart Failure
Case studies in advanced monitoring: OptiVol.
Clinical trials update from the American College of Cardiology meeting: CARE-HF and the remission of heart failure, Women's Health Study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER.
Heart Transplantation from Biventricular Support in Infant with Novel SMYD1 Mutation.
Histone methyltransferase Smyd1 regulates mitochondrial energetics in the heart.
Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study.
The chromatin-binding protein Smyd1 restricts adult mammalian heart growth.
Theodore E. Woodward Award: Coming in out of the rain relieving congestion in heart failure.
Heart Septal Defects, Ventricular
Clinical application of targeted next-generation sequencing on fetuses with congenital heart defects.
Hematologic Neoplasms
Chromatin-regulating proteins as targets for cancer therapy.
Cryptic recurrent ACIN1-NUTM1 fusions in non KMT2A-rearranged infant acute lymphoblastic leukemia.
Distinct functions of histone H3, lysine 4 methyltransferases in normal and malignant hematopoiesis.
Epigenetic modifiers in normal and malignant hematopoiesis.
Specific inhibition of DPY30 activity by ASH2L-derived peptides suppresses blood cancer cell growth.
t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?
Hematoma, Subdural
Oral factor Xa inhibitors and risk of subdural hematoma: COMPASS trial results and meta-analysis.
Hepatitis B
A Novel lncRNA IHS Promotes Tumor Proliferation and Metastasis in HCC by Regulating the ERK- and AKT/GSK-3?-Signaling Pathways.
A virome-wide clonal integration analysis platform for discovering cancer viral etiology.
Hepatitis B virus X protein upregulates expression of SMYD3 and C-MYC in HepG2 cells.
Overexpression of SMYD3 Is Predictive of Unfavorable Prognosis in Hepatocellular Carcinoma.
The SMYD3 VNTR 3/3 polymorphism confers an increased risk and poor prognosis of hepatocellular carcinoma in a Chinese population.
Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma.
[Induction of SMYD3 by hepatitis B virus X gene in HepG2 cells.]
Hepatitis C
Epigenetic regulation of miR-124 by Hepatitis C Virus core protein promotes migration and invasion of intrahepatic cholangiocarcinoma cells by targeting SMYD3.
Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells.
The lysine methyltransferase SMYD3 interacts with hepatitis C virus NS5A and is a negative regulator of viral particle production.
Herpes Simplex
Barrier-to-Autointegration Factor 1 (BAF/BANF1) Promotes Association of the SETD1A Histone Methyltransferase with Herpes Simplex Virus Immediate-Early Gene Promoters.
Dot1l Aggravates Keratitis Induced by Herpes Simplex Virus Type 1 in Mice via p38 MAPK-Mediated Oxidative Stress.
Herpes Zoster
Maternal DOT1L is dispensable for mouse development.
Histiocytic Sarcoma
Primary splenic histiocytic sarcoma associated with hemophagocytic lymphohistiocytosis: A case report and review of literature of next-generation sequencing involving FLT3, NOTCH2, and KMT2A mutations.
Hodgkin Disease
ASH2L drives proliferation and sensitivity to bleomycin and other genotoxins in Hodgkin's lymphoma and testicular cancer cells.
Correction to: ASH2L drives proliferation and sensitivity to bleomycin and other genotoxins in Hodgkin's lymphoma and testicular cancer cells.
Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?
Holoprosencephaly
Holoprosencephaly in Kabuki syndrome.
Novel heterozygous variants in KMT2D associated with holoprosencephaly.
Hyperglycemia
Distinguishing Hyperglycemic Changes by Set7 in Vascular Endothelial Cells.
Hyperglycinemia, Nonketotic
Identification of a RAI1-associated disease network through integration of exome sequencing, transcriptomics, and 3D genomics.
Hypersensitivity
ASH1L histone methyltransferase regulates the handoff between damage recognition factors in global-genome nucleotide excision repair.
Histone methyltransferase DOT1L drives recovery of gene expression after a genotoxic attack.
SMYD3 Promotes Homologous Recombination via Regulation of H3K4-mediated Gene Expression.
Hypertension
Navigating the uncharted waters of combination therapy in pulmonary arterial hypertension: COMPASS or dead-reckoning.
[Selection of psychoemotional load test for the diagnosis of hypertension]
Hypertension, Pulmonary
Megakaryocytic leukemia 1 directs a histone h3 lysine 4 methyltransferase complex to regulate hypoxic pulmonary hypertension.
Hypertrichosis
A de novo Mutation in KMT2A (MLL) in monozygotic twins with Wiedemann-Steiner syndrome.
Advanced bone age in a girl with Wiedemann-Steiner syndrome and an exonic deletion in KMT2A (MLL).
Broad neurodevelopmental features and cortical anomalies associated with a novel de novo KMT2A variant in Wiedemann-Steiner syndrome.
Expanding the genotypic and phenotypic spectrum in a diverse cohort of 104 individuals with Wiedemann-Steiner syndrome.
Further delineation of the phenotype of truncating KMT2A mutations: The extended Wiedemann-Steiner syndrome.
Growth hormone deficiency as a cause for short stature in Wiedemann-Steiner Syndrome.
RNA Sequencing and Pathway Analysis Identify Important Pathways Involved in Hypertrichosis and Intellectual Disability in Patients with Wiedemann-Steiner Syndrome.
Wiedemann-Steiner syndrome with a novel pathogenic variant in KMT2A: a case report.
Hypertriglyceridemia
Significant Quality of Life Improvement Observed in a Patient With FCS Associated With a Marked Reduction in Triglycerides.
Hypoglycemia
Hypoglycemia and Dandy-Walker variant in a Kabuki syndrome patient: a case report.
Neonatal case of novel KMT2D mutation in Kabuki syndrome with severe hypoglycemia.
Neonatal hyperinsulinemic hypoglycemia: case report of kabuki syndrome due to a novel KMT2D splicing-site mutation.
Hypogonadism
Peripheral Precocious Puberty of Ovarian Origin in a Series of 18 Girls: Exome Study Finds Variants in Genes Responsible for Hypogonadotropic Hypogonadism.
Hypoparathyroidism
Phenotypic expansion of KMT2D-related disorder: Beyond Kabuki syndrome.
Hypoplastic Left Heart Syndrome
Cancer Management in Kabuki Syndrome: The First Case of Wilms Tumor and a Literature Review.
Hypothyroidism
A de novo KMT2D mutation in a girl with Kabuki syndrome associated with endocrine symptoms: a case report.
IgA Deficiency
Defects of B-cell terminal differentiation in patients with type-1 Kabuki syndrome.
Infections
Barrier-to-Autointegration Factor 1 (BAF/BANF1) Promotes Association of the SETD1A Histone Methyltransferase with Herpes Simplex Virus Immediate-Early Gene Promoters.
Dot1l Aggravates Keratitis Induced by Herpes Simplex Virus Type 1 in Mice via p38 MAPK-Mediated Oxidative Stress.
Exploring new targets for the treatment of hepatitis-B virus and hepatitis-B virus-associated hepatocellular carcinoma: A new perspective in bioinformatics.
Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells.
Interferon-? Stimulation Elicited by the Influenza Virus Is Regulated by the Histone Methylase Dot1L through the RIG-I-TRIM25 Signaling Axis.
Notch ligand Delta-like 4 induces epigenetic regulation of Treg cell differentiation and function in viral infection.
Quantitative Proteomic Discovery of Dynamic Epigenome Changes that Control Human Cytomegalovirus (HCMV) Infection.
Regulation of disease-responsive genes mediated by epigenetic factors: interaction of Arabidopsis-Pseudomonas.
SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9.
Targeting the Histone Methyltransferase Disruptor of Telomeric Silencing 1-Like Restricts Avian Leukosis Virus Subgroup J Replication by Restoring the Innate Immune Response in Chicken Macrophages.
The DOT1L inhibitor Pinometostat decreases the host-response against infections: Considerations about its use in human therapy.
The Methyltransferase DOT1L Controls Activation and Lineage Integrity in CD4+ T Cells during Infection and Inflammation.
The SMYD3 VNTR 3/3 polymorphism confers an increased risk and poor prognosis of hepatocellular carcinoma in a Chinese population.
Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma.
Infertility
A mouse speciation gene encodes a meiotic histone H3 methyltransferase.
A Mutation of the Prdm9 Mouse Hybrid Sterility Gene Carried by a Transgene.
A Role for Caenorhabditis elegans COMPASS in Germline Chromatin Organization.
Accelerated evolution of the Prdm9 speciation gene across diverse metazoan taxa.
Characterization of Prdm9 in equids and sterility in mules.
Construction of PRDM9 allele-specific recombination maps in cattle using large-scale pedigree analysis and genome-wide single sperm genomics.
Copy-number variation introduced by long transgenes compromises mouse male fertility independently of pachytene checkpoints.
Evolutionary dynamics of meiotic recombination hotspots regulator PRDM9 in bovids.
Extraordinary molecular evolution in the PRDM9 fertility gene.
Genomic and chromatin features shaping meiotic double-strand break formation and repair in mice.
High diversity at PRDM9 in chimpanzees and bonobos.
Histone methyltransferase PRDM9 is not essential for meiosis in male mice.
Hybrid sterility genes in mice (Mus musculus): a peculiar case of PRDM9 incompatibility.
Hybrid Sterility Locus on Chromosome X Controls Meiotic Recombination Rate in Mouse.
Interallelic and intergenic incompatibilities of the Prdm9 (Hst1) gene in mouse hybrid sterility.
Molecular Basis for the Regulation of the H3K4 Methyltransferase Activity of PRDM9.
Pinpointing the PRDM9-PRDM7 Gene Duplication Event During Primate Divergence.
Prdm9 controls activation of mammalian recombination hotspots.
Prdm9 incompatibility controls oligospermia and delayed fertility but no selfish transmission in mouse intersubspecific hybrids.
Prdm9 inter-subspecific interactions in hybrid male sterility of house mouse.
Prdm9 Polymorphism Unveils Mouse Evolutionary Tracks.
PRDM9, a driver of the genetic map.
Rat PRDM9 shapes recombination landscapes, duration of meiosis, gametogenesis, and age of fertility.
Re-engineering the zinc fingers of PRDM9 reverses hybrid sterility in mice.
Reverse genetics reveals single gene of every candidate on Hybrid sterility, X Chromosome QTL 2 (Hstx2) are dispensable for spermatogenesis.
Single Nucleotide Polymorphisms in PRDM9 (MEISETZ) in Patients with Nonobstructive Azoospermia.
The pioneering role of PRDM9 indel mutations in tarsier evolution.
Trimethylation of Histone H3 Lysine 36 by Human Methyltransferase PRDM9.
X marks the spot: PRDM9 rescues hybrid sterility by finding hidden treasure in the genome.
Zinc Finger Domain of the PRDM9 Gene on Chromosome 1 Exhibits High Diversity in Ruminants but Its Paralog PRDM7 Contains Multiple Disruptive Mutations.
Infertility, Female
Setd1b, encoding a histone 3 lysine 4 methyltransferase, is a maternal effect gene required for the oogenic gene expression program.
Infertility, Male
Accelerated evolution of the Prdm9 speciation gene across diverse metazoan taxa.
Bos taurus-indicus hybridization correlates with intralocus sexual-conflict effects of PRDM9 on male and female fertility in Holstein cattle.
Cisplatin-induced DNA double-strand breaks promote meiotic chromosome synapsis in PRDM9-controlled mouse hybrid sterility.
Extraordinary molecular evolution in the PRDM9 fertility gene.
Genetic Dissection of Hybrid Male Sterility Across Stages of Spermatogenesis.
Genomic Structure of Hstx2 Modifier of Prdm9-Dependent Hybrid Male Sterility in Mice.
Prdm9 inter-subspecific interactions in hybrid male sterility of house mouse.
Rare allelic forms of PRDM9 associated with childhood leukemogenesis.
X chromosome control of meiotic chromosome synapsis in mouse inter-subspecific hybrids.
Influenza, Human
Epigenetic control of influenza virus: role of H3K79 methylation in interferon-induced antiviral response.
Interferon-? Stimulation Elicited by the Influenza Virus Is Regulated by the Histone Methylase Dot1L through the RIG-I-TRIM25 Signaling Axis.
The DOT1L inhibitor Pinometostat decreases the host-response against infections: Considerations about its use in human therapy.
Insulin Resistance
Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in mice.
Intellectual Disability
A chromosome 1q22 microdeletion including ASH1L is associated with intellectual disability in a Chinese family.
A novel de novo frameshift variant in SETD1B causes epilepsy.
A novel deletion mutation in KMT2A identified in a child with ID/DD and blood eosinophilia.
An atypical 12q24.31 microdeletion implicates six genes including a histone demethylase KDM2B and a histone methyltransferase SETD1B in syndromic intellectual disability.
ASH1L mutation caused seizures and intellectual disability in twin sisters.
Breast cancer information and support needs for women with intellectual disabilities: a scoping study.
Clinical Characteristics and Genotype-Phenotype Correlation in Children with KMT2E Gene-Related Neurodevelopmental Disorders: Report of Two New Cases and Review of Published Literature.
De novo loss-of-function variants of ASH1L are associated with an emergent neurodevelopmental disorder.
De novo variants in SETD1B are associated with intellectual disability, epilepsy and autism.
De novo variants in SETD1B cause intellectual disability, autism spectrum disorder, and epilepsy with myoclonic absences.
Delineating the molecular and phenotypic spectrum of the SETD1B-related syndrome.
Expanding the genotypic and phenotypic spectrum in a diverse cohort of 104 individuals with Wiedemann-Steiner syndrome.
Expression pattern of Kmt2d in murine craniofacial tissues.
Frequency and phenotypic spectrum of KMT2B dystonia in childhood: A single-center cohort study.
Functional convergence of histone methyltransferases EHMT1 and KMT2C involved in intellectual disability and autism spectrum disorder.
Growth hormone deficiency as a cause for short stature in Wiedemann-Steiner Syndrome.
Histone Lysine Methylases and Demethylases in the Landscape of Human Developmental Disorders.
Identification of a RAI1-associated disease network through integration of exome sequencing, transcriptomics, and 3D genomics.
Kabuki Syndrome-Clinical Review with Molecular Aspects.
Kabuki syndrome: international consensus diagnostic criteria.
Loss of histone methyltransferase ASH1L in the developing mouse brain causes autistic-like behaviors.
Molecular and cellular issues of KMT2A variants involved in Wiedemann-Steiner syndrome.
Mutually suppressive roles of KMT2A and KDM5C in behaviour, neuronal structure, and histone H3K4 methylation.
Novel karyotypes of partial monosomy 21 and partial monosomy 1 and underlying etiology.
Novel MCA/ID syndrome with ASH1L mutation.
ODLURO syndrome: personal experience and review of the literature.
RNA Sequencing and Pathway Analysis Identify Important Pathways Involved in Hypertrichosis and Intellectual Disability in Patients with Wiedemann-Steiner Syndrome.
Role of Ash1l in Tourette syndrome and other neurodevelopmental disorders.
SETD1B-associated neurodevelopmental disorder.
Unmasking Kabuki syndrome.
Wiedemann-Steiner syndrome with a novel pathogenic variant in KMT2A: a case report.
Intracranial Hemorrhages
Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both.
Ischemic Attack, Transient
COMPASS-CP: An Electronic Application to Capture Patient-Reported Outcomes to Develop Actionable Stroke and Transient Ischemic Attack Care Plans.
Hospital recruitment for a pragmatic cluster-randomized clinical trial: Lessons learned from the COMPASS study.
Patient Factors Associated With Attendance at a Comprehensive Postacute Stroke Visit: Insight From the Vanguard Site.
Ischemic Stroke
Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial.
External applicability of the COMPASS trial: the Western Denmark Heart Registry.
Meta-Analysis of Genome-Wide Association Studies Identifies Genetic Risk Factors for Stroke in African Americans.
Joint Diseases
DOT1L safeguards cartilage homeostasis and protects against osteoarthritis.
Keratitis
Dot1l Aggravates Keratitis Induced by Herpes Simplex Virus Type 1 in Mice via p38 MAPK-Mediated Oxidative Stress.
Keratitis, Herpetic
Dot1l Aggravates Keratitis Induced by Herpes Simplex Virus Type 1 in Mice via p38 MAPK-Mediated Oxidative Stress.
Kidney Diseases
Critical roles of SMYD2 lysine methyltransferase in mediating renal fibroblast activation and kidney fibrosis.
Kidney Diseases, Cystic
Acquired Cystic Kidney Disease-associated Renal Cell Carcinoma (ACKD-RCC) Harbor Recurrent Mutations in KMT2C and TSC2 Genes.
Kidney Neoplasms
Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.
SETD2, GIGYF2, FGFR3, BCR, KMT2C, and TSC2 as candidate genes for differentiating multilocular cystic renal neoplasm of low malignant potential from clear cell renal cell carcinoma with cystic change.
Klatskin Tumor
Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells.
Knee Dislocation
Placement of a Compass Knee Hinge: Surgical Technique.
Use of a hinged external knee fixator after surgery for knee dislocation.
Kyphosis
Goniometer evaluation of thoracic kyphosis and lumbar lordosis in subjects during growth age: a validity study.
Language Development Disorders
Clinical Characteristics and Genotype-Phenotype Correlation in Children with KMT2E Gene-Related Neurodevelopmental Disorders: Report of Two New Cases and Review of Published Literature.
Delineating the molecular and phenotypic spectrum of the SETD1B-related syndrome.
SETD1B-associated neurodevelopmental disorder.
Leukemia
A case of pediatric acute myeloid leukemia with t(11;16)(q23;q24) leading to a novel KMT2A-USP10 fusion gene.
A higher-order configuration of the heterodimeric DOT1L-AF10 coiled-coil domains potentiates their leukemogenenic activity.
A KMT2A-AFF1 gene regulatory network highlights the role of core transcription factors and reveals the regulatory logic of key downstream target genes.
A Medicinal Chemistry Perspective for Targeting Histone H3 Lysine-79 Methyltransferase DOT1L.
A new variant of KMT2A(MLL)-FLNA fusion transcript in acute myeloid leukemia with ins(X;11)(q28;q23q23).
A novel non-SET domain multi-subunit methyltransferase required for sequential nucleosomal histone H3 methylation by the mixed lineage leukemia protein-1 (MLL1) core complex.
A Patient with Kabuki Syndrome Mutation Presenting with Very Severe Aplastic Anemia.
A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial.
A role for DOT1L in MLL-rearranged leukemias.
A subset of mixed lineage leukemia proteins has plant homeodomain (PHD)-mediated E3 ligase activity.
A systems biology approach for elucidating the interaction of curcumin with Fanconi anemia FANC G protein and the key disease targets of leukemia.
Aberrant Activity of Histone-Lysine N-Methyltransferase 2 (KMT2) Complexes in Oncogenesis.
Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.
Activation of the lysosome-associated membrane protein LAMP5 by DOT1L serves as a bodyguard for MLL fusion oncoproteins to evade degradation in leukemia.
Acute leukemias harboring KMT2A/MLLT10 fusion: a 10-year experience from a single genomics laboratory.
Acute lymphoblastic leukemia in infants: a quarter century of nationwide efforts in Japan.
Acute myeloid leukemia with t(10;11)(p11-12;q23.3): Results of Russian Pediatric AML registration study.
An Original Complex Rearrangement Involving Chromosomes 9, 11, and 14, Harboring a Complex KMT2A Gene Rearrangement in an Infant With Mixed-phenotype Acute Leukemia.
Ash1l controls quiescence and self-renewal potential in hematopoietic stem cells.
ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.
ASH2L-Promoted HOXC8 Gene Expression Plays a Role in Mixed Lineage Leukemia-Rearranged Acute Leukemia.
ASH2L: alternative splicing and downregulation during induced megakaryocytic differentiation of multipotential leukemia cell lines.
Biochemical perspectives on targeting KMT2 methyltransferases in cancer.
Bromo-deaza-SAH: A potent and selective DOT1L inhibitor.
BTK, NUTM2A, and PRPF19 Are Novel KMT2A Partner Genes in Childhood Acute Leukemia.
C1188D mutation abolishes specific recognition between MLL1-CXXC domain and CpG site by inducing conformational switch of flexible N-terminal.
Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a KMT2A-Rearranged Leukemia.
Characterization of a novel WDR5-binding site that recruits RbBP5 through a conserved motif to enhance methylation of histone H3 lysine 4 by mixed lineage leukemia protein-1.
Characterizing the Role of SMYD2 in Mammalian Embryogenesis-Future Directions.
Chimeric antigen receptor T-cell therapy for marrow and extramedullary relapse of infant acute lymphoblastic leukemia.
Chromatin-regulating proteins as targets for cancer therapy.
Cleaving for growth: threonine aspartase 1-a protease relevant for development and disease.
Clinicopathologic and prognostic features of TdT-negative pediatric B-lymphoblastic leukemia.
Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Comprehensive genetic analysis of donor cell derived leukemia with KMT2A rearrangement.
Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L.
Conserved crosstalk between histone deacetylation and H3K79 methylation generates DOT1L-dose dependency in HDAC1-deficient thymic lymphoma.
Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia.
Cooperativity in transcription factor binding to the coactivator CREB-binding protein (CBP). The mixed lineage leukemia protein (MLL) activation domain binds to an allosteric site on the KIX domain.
Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target.
Correction to: The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
Crucial roles of mixed-lineage leukemia 3 and 4 as epigenetic switches of the hepatic circadian clock controlling bile acid homeostasis in mice.
Cryptic and atypical KMT2A-USP2 and KMT2A-USP8 rearrangements identified by mate pair sequencing in infant and childhood leukemia.
Cryptic recurrent ACIN1-NUTM1 fusions in non KMT2A-rearranged infant acute lymphoblastic leukemia.
Cyp33 binds AU-rich RNA motifs via an extended interface that competitively disrupts the gene repressive Cyp33-MLL1 interaction in vitro.
Cytogenomic characterization of double minute heterogeneity in therapy related acute myeloid leukemia.
De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia.
Design, synthesis and anti leukemia cells proliferation activities of pyrimidylaminoquinoline derivatives as DOT1L inhibitors.
Detection of gene rearrangements in targeted clinical next-generation sequencing.
Discovery of a Selective Inhibitor for the YEATS Domains of ENL/AF9.
Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity.
Discovery of Novel Disruptor of Silencing Telomeric 1-Like (DOT1L) Inhibitors using a Target-Specific Scoring Function for the (S)-Adenosyl-l-methionine (SAM)-Dependent Methyltransferase Family.
Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.
Discovery of potent DOT1L inhibitors by AlphaLISA based High Throughput Screening assay.
Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.
Disruptor of telomeric silencing 1-like (DOT1L): disclosing a new class of non-nucleoside inhibitors by means of ligand-based and structure-based approaches.
Distinct functions of histone H3, lysine 4 methyltransferases in normal and malignant hematopoiesis.
Disturbing the histone code in leukemia: translocations and mutations affecting histone methyl transferases.
DOT1L and H3K79 Methylation in Transcription and Genomic Stability.
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
DOT1L complex regulates transcriptional initiation in human erythroleukemic cells.
DOT1L histone methyltransferase regulates the expression of BCAT1 and is involved in sphere formation and cell migration of breast cancer cell lines.
DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway.
DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation.
DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells.
DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.
Drug discovery in rare indications: opportunities and challenges.
Dysregulation of the DNA Damage Response and KMT2A Rearrangement in Fetal Liver Hematopoietic Cells.
Elucidating the Importance of DOT1L Recruitment in MLL-AF9 Leukemia and Hematopoiesis.
Epigenetic changes in human model KMT2A leukemias highlight early events during leukemogenesis.
Epigenetic modifiers in normal and malignant hematopoiesis.
Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development.
Epigenetic regulation of protein translation in KMT2A-rearranged AML.
Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia.
Establishment and characterization of a DOT1L inhibitor-sensitive human acute monocytic leukemia cell line YBT-5 with a novel KMT2A-MLLT3 fusion.
Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target.
Expression and clinical role of RBQ3 in gliomas.
Filamins but Not Janus Kinases Are Substrates of the ASB2? Cullin-Ring E3 Ubiquitin Ligase in Hematopoietic Cells.
First case of B ALL with KMT2A-MAML2 rearrangement: a case report.
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Functional interdependence of BRD4 and DOT1L in MLL leukemia.
Functional interrogation of HOXA9 regulome in MLLr leukemia via reporter-based CRISPR/Cas9 screen.
Genetic mutational analysis of pediatric acute lymphoblastic leukemia from a single center in China using exon sequencing.
Genome-Wide Analysis of Menin Binding Provides Insights into MEN1 Tumorigenesis.
Genome-wide association and functional studies identify the DOT1L gene to be involved in cartilage thickness and hip osteoarthritis.
Glucocorticoids uncover a critical role for ASH2L on BCL-X expression regulation in leukemia cells.
High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.
High-efficiency CRISPR induction of t(9;11) chromosomal translocations and acute leukemias in human blood stem cells.
Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis.
Histone H3K4 methyltransferase Mll1 regulates protein glycosylation and tunicamycin-induced apoptosis through transcriptional regulation.
Histone H3K4 Methyltransferases as Targets for Drug-Resistant Cancers.
Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer.
Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4.
How I treat infant leukemia.
Identification of a Cryptic Insertion ins(11;X)(q23;q28q12) Resulting in a KMT2A-FLNA Fusion in a 13-Month-Old Child with Acute Myelomonocytic Leukemia.
Identification of a novel KMT2A/GIMAP8 gene fusion in a pediatric patient with acute undifferentiated leukemia.
Identification of KMT2A-ARHGEF12 fusion in a child with a high-grade B-cell lymphoma.
Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
Inhibition of Dot1L Alleviates Fulminant Hepatitis Through Myeloid-Derived Suppressor Cells.
Inhibition of DOT1L and PRMT5 promote synergistic anti-tumor activity in a human MLL leukemia model induced by CRISPR/Cas9.
Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML.
Integrated Analysis of Genetic Abnormalities of the Histone Lysine Methyltransferases in Prostate Cancer.
KAT8 Regulates Androgen Signaling in Prostate Cancer Cells.
KIX-mediated assembly of the CBP-CREB-HTLV-1 tax coactivator-activator complex.
KMT2A (MLL)-MLLT1 rearrangement in blastic plasmacytoid dendritic cell neoplasm.
KMT2A-ARHGEF12, a therapy related fusion with poor prognosis.
KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.
Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression.
Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
lncRNA ZEB1-AS1 Was Suppressed by p53 for Renal Fibrosis in Diabetic Nephropathy.
Low concentrations of permethrin and malathion induce numerical and structural abnormalities in KMT2A and IGH genes in vitro.
Low expression of ASH2L protein correlates with a favorable outcome in acute myeloid leukemia.
LSD1 inhibition exerts its anti-leukemic effect by recommissioning PU.1- and C/EBP?-dependent enhancers in AML.
Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in MLL-Rearranged Leukemia.
Mechanisms of transcriptional regulation by MLL and its disruption in acute leukemia.
Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors.
Menin expression is regulated by transforming growth factor beta signaling in leukemia cells.
Menin regulates the function of hematopoietic stem cells and lymphoid progenitors.
Mixed lineage leukemia protein in normal and leukemic stem cells.
MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition.
MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia.
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.
MLL-TFE3: a novel and aggressive KMT2A fusion identified in infant leukemia.
MLL/KMT2A translocations in diffuse large B-cell lymphomas.
MLL/WDR5 Complex Regulates Kif2A Localization to Ensure Chromosome Congression and Proper Spindle Assembly during Mitosis.
MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.
MLL4-associated condensates counterbalance Polycomb-mediated nuclear mechanical stress in Kabuki syndrome.
Molecular characterization of KMT2A fusion partner genes in 13 cases of pediatric leukemia with complex or cryptic karyotypes.
Monocytic Acute Myeloid Leukemias with KM2TA Translocations to Chromosome 17q that May Clinically Mimic Acute Promyelocytic Leukemia.
Neuronal Kmt2a/Mll1 histone methyltransferase is essential for prefrontal synaptic plasticity and working memory.
Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia.
Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor.
Novel DOT1L ReceptorNatural Inhibitors Involved in Mixed Lineage Leukemia: a Virtual Screening, Molecular Docking and Dynamics Simulation Study.
Novel SH3 protein encoded by the AF3p21 gene is fused to the mixed lineage leukemia protein in a therapy-related leukemia with t(3;11) (p21;q23).
Novel sub-cellular localizations and intra-molecular interactions may define new functions of Mixed Lineage Leukemia protein.
Nucleoside and Non-Nucleoside DOT1L Inhibitors: Dawn of MLLrearranged Leukemia.
Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia.
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
Preclinical Pharmacokinetics and Pharmacodynamics of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl Methionine Competitive Inhibitor of DOT1L.
Protein-arginine Methyltransferase 1 (PRMT1) Methylates Ash2L, a Shared Component of Mammalian Histone H3K4 Methyltransferase Complexes.
Quantification of NG2-positivity for the precise prediction of KMT2A gene rearrangements in childhood acute leukemia.
Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis.
Recent progress in the treatment of infant acute lymphoblastic leukemia.
Regulation of HOXA2 gene expression by the ATP-dependent chromatin remodeling enzyme CHD8.
Regulation of IL-20 Expression by Estradiol through KMT2B-Mediated Epigenetic Modification.
Regulation of Wnt signaling target gene expression by the histone methyltransferase DOT1L.
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.
Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation.
Requirement for MLL3 in p53 regulation of hepatic expression of small heterodimer partner and bile acid homeostasis.
Rerouting DOT1L inhibitors in leukemia.
Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.
Rewiring the Epigenetic Networks in MLL-Rearranged Leukemias: Epigenetic Dysregulation and Pharmacological Interventions.
Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies.
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
SETD1A Interacts with Cyclin K to Promote Leukemia Cell Survival.
Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth.
Smyd2 is a Myc-regulated gene critical for MLL-AF9 induced leukemogenesis.
SMYD2 lysine methyltransferase regulates leukemia cell growth and regeneration after genotoxic stress.
Somatic alterations and dysregulation of epigenetic modifiers in cancers.
Somatic cancer mutations in the MLL1 histone methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L complex.
Somatic Mutations of the Mixed-Lineage Leukemia 3 (MLL3) Gene in Primary Breast Cancers.
Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML.
Stabilizing the Mixed Lineage Leukemia Protein.
Structural and functional analysis of the DOT1L-AF10 complex reveals mechanistic insights into MLL-AF10-associated leukemogenesis.
Structural Basis for Recognition of Ubiquitylated Nucleosome by Dot1L Methyltransferase.
Structural Basis of Dot1L Stimulation by Histone H2B Lysine 120 Ubiquitination.
Structural Characterization of the Loop at the Alpha-Subunit C-Terminus of the Mixed Lineage Leukemia Protein Activating Protease Taspase1.
Structure of WDR5 bound to mixed lineage leukemia protein-1 peptide.
Structure, Activity and Function of the MLL2 (KMT2B) Protein Lysine Methyltransferase.
Structure-guided development of YEATS domain inhibitors by targeting ?-?-? stacking.
Structure-Guided DOT1L Probe Optimization by Label-Free Ligand Displacement.
Substituted purine and 7-deazapurine compounds as modulators of epigenetic enzymes: a patent evaluation (WO2012075381).
Suppression of Mll1-Complex by Stat3/Cebp?-Induced miR-21a/21b/181b Maintains the Accumulation, Homeostasis, and Immunosuppressive Function of Polymorphonuclear Myeloid-Derived Suppressor Cells.
Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein.
Synthesis and Structure-Activity Relationship Investigation of Adenosine-Containing Inhibitors of Histone Methyltransferase DOT1L.
Synthesis, Activity and Metabolic Stability of Non-Ribose Containing Inhibitors of Histone Methyltransferase DOT1L.
TALEN-Mediated FLAG-Tagging of Endogenous Histone Methyltransferase DOT1L.
Targeted Disruption of the Interaction Between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.
Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.
Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development.
Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia.
Targeting recruitment of Disruptor Of Telomeric silencing 1-Like (DOT1L): Characterizing the interactions between DOT1L and Mixed Lineage Leukemia (MLL) fusion proteins.
The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations.
The amino terminus of the mixed lineage leukemia protein (MLL) promotes cell cycle arrest and monocytic differentiation.
The combination of dibenzazepine and a DOT1L inhibitor enables a stable maintenance of human naïve-state pluripotency in non-hypoxic conditions.
The diverse functions of Dot1 and H3K79 methylation.
The DOT1L inhibitor Pinometostat decreases the host-response against infections: Considerations about its use in human therapy.
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.
The emerging roles of DOT1L in leukemia and normal development.
The Histone H3 Lysine 4 Presenter WDR5 as an Oncogenic Protein and Novel Epigenetic Target in Cancer.
The Histone Methyltransferase DOT1L Is Essential for Humoral Immune Responses.
The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness.
The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target.
The identification of novel small-molecule inhibitors targeting WDR5-MLL1 interaction through fluorescence polarization based high-throughput screening.
The Importin-alpha/Nucleophosmin switch controls Taspase1 protease function.
The internal interaction in RBBP5 regulates assembly and activity of MLL1 methyltransferase complex.
The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
The lysine methyltransferase SMYD2 is required for normal lymphocyte development and survival of hematopoietic leukemias.
The mechanism of binding of the KIX domain to the mixed lineage leukemia protein and its allosteric role in the recognition of c-Myb.
The protective role of DOT1L in UV-induced melanomagenesis.
The role of autophagy in targeted therapy for acute myeloid leukemia.
The role of DOT1L in the maintenance of leukemia gene expression.
The role of menin in hematopoiesis.
The super elongation complex (SEC) and MLL in development and disease.
The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.
The trithorax group protein Ash2l is essential for pluripotency and maintaining open chromatin in embryonic stem cells.
The upstreams and downstreams of H3K79 methylation by DOT1L.
Therapeutic implications of menin inhibition in acute leukemias.
Therapy-induced Deletion in 11q23 Leading to Fusion of KMT2A With ARHGEF12 and Development of B Lineage Acute Lymphoplastic Leukemia in a Child Treated for Acute Myeloid Leukemia Caused by t(9;11)(p21;q23)/KMT2A-MLLT3.
Therapy-related acute lymphoblastic leukemia: Where do we stand with regards to its definition and characterization?
Uncommon somatic mutations in metastatic NUT midline carcinoma.
Unique Role of the WD-40 Repeat Protein 5 (WDR5) Subunit within the Mixed Lineage Leukemia 3 (MLL3) Histone Methyltransferase Complex.
UTX and MLL4 Coordinately Regulate Transcriptional Programs for Cell Proliferation and Invasiveness in Breast Cancer Cells.
[Acute leukemia of infants and neonates].
[Effect of DOT1L Gene Silence on Proliferation of Acute Monocytic Leukemia Cell Line THP-1].
Leukemia, Lymphocytic, Chronic, B-Cell
CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells.
High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia.
Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia.
STAT3 promotes chronic lymphocytic leukemia progression through upregulating SMYD3 expression.
STAT3-induced SMYD3 transcription enhances chronic lymphocytic leukemia cell growth in vitro and in vivo.
Leukemia, Megakaryoblastic, Acute
Megakaryocytic leukemia 1 directs a histone h3 lysine 4 methyltransferase complex to regulate hypoxic pulmonary hypertension.
MKL1 mediates TNF-? induced pro-inflammatory transcription by bridging the crosstalk between BRG1 and WDR5.
Leukemia, Monocytic, Acute
Establishment and characterization of a DOT1L inhibitor-sensitive human acute monocytic leukemia cell line YBT-5 with a novel KMT2A-MLLT3 fusion.
[Effect of DOT1L Gene Silence on Proliferation of Acute Monocytic Leukemia Cell Line THP-1].
Leukemia, Myeloid
An uncommon t(9;11)(p24;q22) with monoallelic loss of ATM and KMT2A genes in a child with myelodysplastic syndrome/acute myeloid leukemia who evolved from Fanconi anemia.
Bromo-deaza-SAH: A potent and selective DOT1L inhibitor.
DOTting the path to doom: how acceleration of histone methylation leads to leukemia.
Early-age Acute Leukemia: Revisiting Two Decades of the Brazilian Collaborative Study Group.
Glucocorticoids uncover a critical role for ASH2L on BCL-X expression regulation in leukemia cells.
Leukemia, Myeloid, Acute
A KMT2A-AFF1 gene regulatory network highlights the role of core transcription factors and reveals the regulatory logic of key downstream target genes.
A lineage switch from NPM1-mutant acute myeloid leukemia to acute T-cell lymphoblastic leukemia with KMT2D and ARID2 mutant.
A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response.
A Novel and Cytogenetically Cryptic t(7;21)(q36.1;q22) Disrupting RUNX1 in Acute Myeloid Leukemia.
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.
A pediatric case of acute myeloid leukemia with KMT2A gene rearrangement t(10;11) and 16p11.2 microdeletion syndrome.
Acute myeloid leukemia with t(10;11)(p11-12;q23.3): Results of Russian Pediatric AML registration study.
Allogenic Stem Cell Transplantation Abrogates Negative Impact on Outcome of AML Patients with KMT2A Partial Tandem Duplication.
Assessing acute myeloid leukemia susceptibility in rearrangement-driven patients by DNA breakage at topoisomerase II and CCCTC-binding factor/cohesin binding sites.
Clinical Impact of KMT2C and SPRY4 Expression Levels in Intensively Treated Younger Adult Acute Myeloid Leukemia Patients.
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
EPHX1 rs1051740 T>C (Tyr113His) is strongly associated with acute myeloid leukemia and KMT2A rearrangements in early age.
Epigenetic changes in human model KMT2A leukemias highlight early events during leukemogenesis.
Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia.
Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan.
Homogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
KMT2A (MLL) rearrangements observed in pediatric/young adult T-lymphoblastic leukemia/lymphoma: A 10-year review from a single cytogenetic laboratory.
Kmt2c mutations enhance HSC self-renewal capacity and convey a selective advantage after chemotherapy.
Long-term remission of therapy-related acute myeloid leukemia with a new t(11;18)(q23;q21.2) translocation and KMT2A-ME2 (MLL-ME2) fusion gene.
Low expression of ASH2L protein correlates with a favorable outcome in acute myeloid leukemia.
MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.
Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A.
MYC and KMT2A multiple extra copies in acute myeloid leukemia.
Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro.
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.
Smyd2 is a Myc-regulated gene critical for MLL-AF9 induced leukemogenesis.
Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML.
Sudden Unexpected Death in a Child From Acute Myeloid Leukemia.
The role of autophagy in targeted therapy for acute myeloid leukemia.
The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.
Therapy-induced Deletion in 11q23 Leading to Fusion of KMT2A With ARHGEF12 and Development of B Lineage Acute Lymphoplastic Leukemia in a Child Treated for Acute Myeloid Leukemia Caused by t(9;11)(p21;q23)/KMT2A-MLLT3.
Whole transcriptome sequencing reveals a KMT2A-USP2 fusion in infant acute myeloid leukemia.
Leukemia, Myelomonocytic, Acute
Identification of a Cryptic Insertion ins(11;X)(q23;q28q12) Resulting in a KMT2A-FLNA Fusion in a 13-Month-Old Child with Acute Myelomonocytic Leukemia.
Leukemia, Promyelocytic, Acute
The role of autophagy in targeted therapy for acute myeloid leukemia.
Lipoma
A novel protein expression signature differentiates benign lipomas from well-differentiated liposarcomas.
Liposarcoma
A novel protein expression signature differentiates benign lipomas from well-differentiated liposarcomas.
Liver Cirrhosis
High?level SETD1B gene expression is associated with unfavorable prognosis in hepatocellular carcinoma.
Myocardin related transcription factor A programs epigenetic activation of hepatic stellate cells.
Liver Diseases
COMPASS: A Pilot Trial of an Early Palliative Care Intervention for Patients With End-Stage Liver Disease.
Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma.
Liver Neoplasms
A virome-wide clonal integration analysis platform for discovering cancer viral etiology.
Exploring new targets for the treatment of hepatitis-B virus and hepatitis-B virus-associated hepatocellular carcinoma: A new perspective in bioinformatics.
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
Lordosis
Goniometer evaluation of thoracic kyphosis and lumbar lordosis in subjects during growth age: a validity study.
Lung Neoplasms
Comprehensive molecular analysis of genomic profiles and PD-L1 expression in lung adenocarcinoma with a high-grade fetal adenocarcinoma component.
Deficiency of H3K79 Histone Methyltransferase Dot1-like Protein (DOT1L) Inhibits Cell Proliferation.
DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells.
EHMT1 knockdown induces apoptosis and cell cycle arrest in lung cancer cells by increasing CDKN1A expression.
Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.
Histone methyltransferase SETD1A participates in lung cancer progression.
Inhibition of SMYD2 Sensitized Cisplatin to Resistant Cells in NSCLC Through Activating p53 Pathway.
KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer.
Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer.
Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L).
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
RNF213 gene mutation in circulating tumor DNA detected by targeted next-generation sequencing in the assisted discrimination of early-stage lung cancer from pulmonary nodules.
SMYD3 overexpression indicates poor prognosis and promotes cell proliferation, migration and invasion in non?small cell lung cancer.
Smyd3-associated regulatory pathways in cancer.
Suppression of Mll1-Complex by Stat3/Cebp?-Induced miR-21a/21b/181b Maintains the Accumulation, Homeostasis, and Immunosuppressive Function of Polymorphonuclear Myeloid-Derived Suppressor Cells.
The H3K4 methyltransferase SETD1A is required for proliferation of non-small cell lung cancer cells by promoting S-phase progression.
[Health and disease in the Netherlands: the Dutch National Public Health Compass as a source of information]
Lupus Erythematosus, Systemic
Genome-wide association study on Northern Chinese identifies KLF2, DOT1L and STAB2 associated with systemic lupus erythematosus.
[Lupus membranous nephropathy]
Lymphatic Metastasis
Elevated Levels of SET and MYND Domain-Containing Protein 3 Are Correlated with Overexpression of Transforming Growth Factor-?1 in Gastric Cancer.
High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancer.
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.
Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer.
Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer.
Overexpression of the SMYD3 Promotes Proliferation, Migration, and Invasion of Pancreatic Cancer.
Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer.
SMYD2 facilitates cancer cell malignancy and xenograft tumor development through ERBB2-mediated FUT4 expression in colon cancer.
SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma.
SMYD3 promoter hypomethylation is associated with the risk of colorectal cancer.
SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration and invasion in esophageal squamous cell carcinoma.
The role of DOT1L in the proliferation and prognosis of gastric cancer.
Lymphohistiocytosis, Hemophagocytic
Primary splenic histiocytic sarcoma associated with hemophagocytic lymphohistiocytosis: A case report and review of literature of next-generation sequencing involving FLT3, NOTCH2, and KMT2A mutations.
Lymphoma
A Patient with Kabuki Syndrome Mutation Presenting with Very Severe Aplastic Anemia.
Adult High Grade B-cell Lymphoma with Burkitt Lymphoma Signature: Genomic features and Potential Therapeutic Targets.
Collaboration of MYC and RUNX2 in lymphoma simulates T-cell receptor signaling and attenuates p53 pathway activity.
Conserved crosstalk between histone deacetylation and H3K79 methylation generates DOT1L-dose dependency in HDAC1-deficient thymic lymphoma.
Detection of Rare Germline Variants in the Genomes of Patients with B-Cell Neoplasms.
Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis.
Epigenetic modifiers in normal and malignant hematopoiesis.
EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.
Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.
KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas.
KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.
Low concentrations of permethrin and malathion induce numerical and structural abnormalities in KMT2A and IGH genes in vitro.
Matrix Metalloproteinase-9 gene induction by a truncated oncogenic NF-kappaB2 protein involves the recruitment of MLL1 and MLL2 H3K4 histone methyltransferase complexes.
MLL/KMT2A translocations in diffuse large B-cell lymphomas.
Mutational landscape of T-cell lymphoma in mice lacking the DNA mismatch repair gene Mlh1: no synergism with ionizing radiation.
Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK/T-cell lymphoma.
Recurrent mutations in NF-?B pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas.
Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation.
Smyd2 is a Myc-regulated gene critical for MLL-AF9 induced leukemogenesis.
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
Lymphoma, B-Cell
Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.
Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis.
EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.
FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.
KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas.
MLL/KMT2A translocations in diffuse large B-cell lymphomas.
Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and /or BCL6 rearrangements.
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma.
Lymphoma, Follicular
Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.
Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis.
EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.
The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
Lymphoma, Large B-Cell, Diffuse
Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.
Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis.
EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.
FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.
KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas.
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
Lymphoma, Mantle-Cell
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.
Lymphoma, Non-Hodgkin
A virome-wide clonal integration analysis platform for discovering cancer viral etiology.
Studies Identify Non-Hodgkin Lymphoma Suppressor.
The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.
Lymphoma, T-Cell
A Survey of Somatic Mutations in 41 Genes in a Cohort of T-Cell Lymphomas Identifies Frequent Mutations in Genes Involved in Epigenetic Modification.
Lymphopenia
The H3K4 methyltransferase Setd1b is essential for hematopoietic stem and progenitor cell homeostasis in mice.
Lymphoproliferative Disorders
Autoimmune Cytopenias in Chronic Lymphocytic Leukemia: Focus on Molecular Aspects.
Chronic Active Epstein-Barr Virus Infection of T/NK-Cell Type Mimicking Classic Hodgkin Lymphoma: Clinicopathologic and Genetic Features of 8 Cases Supporting a Variant With "Hodgkin/Reed-Sternberg-like" Cells of NK Phenotype.
Somatic mutations in KMT2D and TET2 associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders.
Macular Degeneration
Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research.
Massive Hepatic Necrosis
Inhibition of Dot1L Alleviates Fulminant Hepatitis Through Myeloid-Derived Suppressor Cells.
Medulloblastoma
KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.
MLL4 Is Required to Maintain Broad H3K4me3 Peaks and Super-Enhancers at Tumor Suppressor Genes.
Melanoma
A novel germline variant in the DOT1L gene co-segregating in a Dutch family with a history of melanoma.
Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma.
KMT2A promotes melanoma cell growth by targeting hTERT signaling pathway.
Targeting the Histone Methyltransferase Disruptor of Telomeric Silencing 1-Like Restricts Avian Leukosis Virus Subgroup J Replication by Restoring the Innate Immune Response in Chicken Macrophages.
The protective role of DOT1L in UV-induced melanomagenesis.
Memory Disorders
Vorinostat, a histone deacetylase inhibitor, ameliorates the sociability and cognitive memory in an Ash1L-deletion-induced ASD/ID mouse model.
Mental Retardation, X-Linked
Identification of a RAI1-associated disease network through integration of exome sequencing, transcriptomics, and 3D genomics.
X-Linked Mental Retardation Gene CUL4B Targets Ubiquitylation of H3K4 Methyltransferase Component WDR5 and Regulates Neuronal Gene Expression.
Mesothelioma, Malignant
Analysis of mutations of PARP1, RNF213, PAX8, KMT2C, MTRR in malignant mesothelioma of testicular tunica vaginalis testis.
Microcephaly
Characterization of SETD1A haploinsufficiency in humans and Drosophila defines a novel neurodevelopmental syndrome.
Holoprosencephaly in Kabuki syndrome.
Identification of a RAI1-associated disease network through integration of exome sequencing, transcriptomics, and 3D genomics.
Inhibition of Notch signaling rescues cardiovascular development in Kabuki Syndrome.
Novel MCA/ID syndrome with ASH1L mutation.
Quantitative phenotypic and network analysis of 1q44 microdeletion for microcephaly.
Micrognathism
Small molecule inhibition of RAS/MAPK signaling ameliorates developmental pathologies of Kabuki Syndrome.
Migraine Disorders
A novel intranasal breath-powered delivery system for sumatriptan: a review of technology and clinical application of the investigational product AVP-825 in the treatment of migraine.
AVP-825 breath-powered intranasal delivery system containing 22?mg sumatriptan powder vs 100?mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.
Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered(®) Exhalation Delivery System (Sumatriptan Nasal Powder) vs Oral Sumatriptan.
Evaluating Mean Level and Within-Person Consistency in Migraine Pain Intensity and Migraine-Related Disability for AVP-825 vs Oral Sumatriptan: Results from the COMPASS Study, A Randomized Trial.
Faster Improvement in Migraine Pain Intensity and Migraine-Related Disability at Early Time Points with AVP-825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the COMPASS Study.
Monoclonal Gammopathy of Undetermined Significance
DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.
Movement Disorders
KMT2B rare missense variants in generalized dystonia.
Multiple Myeloma
Absolute quantification of histone PTM marks by MRM-based LC-MS/MS.
DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.
DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway.
Downregulation of MMSET impairs breast cancer proliferation and metastasis through inhibiting Wnt/?-catenin signaling.
MMSET is highly expressed and associated with aggressiveness in neuroblastoma.
NSD2 Is Recruited through Its PHD Domain to Oncogenic Gene Loci to Drive Multiple Myeloma.
NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.
NSD2 promotes osteosarcoma cell proliferation and metastasis by inhibiting E-cadherin expression.
Overexpression of MMSET is Correlation with Poor Prognosis in Hepatocellular Carcinoma.
The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors.
Multiple Sclerosis
Telemedicine for multiple sclerosis patients: assessment using Health Value Compass.
Muscle Hypotonia
Genetic and behavioral characterization of a Kmt2d mouse mutant, a new model for Kabuki Syndrome.
Kabuki Syndrome-Clinical Review with Molecular Aspects.
Kabuki syndrome: international consensus diagnostic criteria.
Novel KDM6A (UTX) mutations and a clinical and molecular review of the X-linked Kabuki syndrome (KS2).
Muscular Atrophy
The methyltransferase SMYD3 mediates the recruitment of transcriptional cofactors at the myostatin and c-Met genes and regulates skeletal muscle atrophy.
Muscular Diseases
Mouse myofibers lacking the SMYD1 methyltransferase are susceptible to atrophy, internalization of nuclei and myofibrillar disarray.
Muscular Dystrophies
The Trithorax protein Ash1L promotes myoblast fusion by activating Cdon expression.
Muscular Dystrophy, Duchenne
The Trithorax protein Ash1L promotes myoblast fusion by activating Cdon expression.
Myelodysplastic Syndromes
Homogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Kmt2c mutations enhance HSC self-renewal capacity and convey a selective advantage after chemotherapy.
Severe granulocytic dysplasia with vacuolar rosettes in a myelodysplastic syndrome with low-copy KMT2A gain.
The role of autophagy in targeted therapy for acute myeloid leukemia.
Myocardial Infarction
Efficacy and Safety of Long-Term Antithrombotic Strategies in Patients With Chronic Coronary Syndrome: A Network Meta-analysis of Randomized Controlled Trials.
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
External applicability of the COMPASS trial: the Western Denmark Heart Registry.
Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease.
Lysine methyltransferase Smyd2 suppresses p53-dependent cardiomyocyte apoptosis.
Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines.
Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. Comparison Trial of Saruplase and Streptokinase (COMASS) Investigators.
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy.
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study.
Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD.
The COMPASS trial: practical considerations for application after coronary artery bypass surgery.
The ST Compass: spatial visualization of ST-segment deviations and estimation of the ST injury vector.
Usefulness of Coronary Artery Calcium to Identify Adults of Sufficiently High Risk for Atherothrombotic Cardiovascular Events to Consider Low-Dose Rivaroxaban Thromboprophylaxis (from MESA).
[Combined Antithrombotic Therapy in Patients with a Stable Atherosclerotic Cardiovascular Diseases: What Direction did COMPASS Show?]
[Current opportunities for secondary prevention of atherothrombotic stroke].
Myocardial Ischemia
The ST Compass: spatial visualization of ST-segment deviations and estimation of the ST injury vector.
[PEGASUS or COMPASS? A guide for a wise clinical choice.]
[The Efficacy of Rivaroxaban in Reducing the Risk of Cardiovascular Events in Patients with Stable Ischemic Heart Disease and Peripheral Disease. Results of the COMPASS Trial].
Myopia
Comparison of the structure-function relationship between compass microperimetry and Humphrey field analyser in myopic open-angle glaucoma eyes.
Nasal Polyps
Autonomic dysfunction as an independent risk factor for uncontrolled inflammation in chronic rhinosinusitis following functional endoscopic sinus surgery.
Nasopharyngeal Carcinoma
Comprehensive high-throughput RNA sequencing analysis reveals contamination of multiple nasopharyngeal carcinoma cell lines with HeLa cell genomes.
Neoplasm Metastasis
A Novel lncRNA IHS Promotes Tumor Proliferation and Metastasis in HCC by Regulating the ERK- and AKT/GSK-3?-Signaling Pathways.
A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer.
Aberrant expression of SETD1A promotes survival and migration of estrogen receptor ?-positive breast cancer cells.
Amplification of SMYD3 promotes tumorigenicity and intrahepatic metastasis of hepatocellular carcinoma via upregulation of CDK2 and MMP2.
ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma.
CBP mediated DOT1L acetylation confers DOT1L stability and promotes cancer metastasis.
Clinical and mutational profiles of adult medulloblastoma groups.
DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression.
Elevated Levels of SET and MYND Domain-Containing Protein 3 Are Correlated with Overexpression of Transforming Growth Factor-?1 in Gastric Cancer.
Epigenetic Role of Histone Lysine Methyltransferase and Demethylase on the Expression of Transcription Factors Associated with the Epithelial-to-Mesenchymal Transition of Lung Adenocarcinoma Metastasis to the Brain.
Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours.
Hesperetin promotes DOT1L degradation and reduces histone H3K79 methylation to inhibit gastric cancer metastasis.
High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancer.
Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4.
Histone Methyltransferase SETD1A Induces Epithelial-Mesenchymal Transition to Promote Invasion and Metastasis Through Epigenetic Reprogramming of Snail in Gastric Cancer.
Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells.
Inhibition of DOT1L by Half-Selenopsammaplin A Analogs Suppresses Tumor Growth and EMT-Mediated Metastasis in Triple-Negative Breast Cancer.
KMT2A histone methyltransferase contributes to colorectal cancer development by promoting cathepsin Z transcriptional activation.
KMT2D inhibits the growth and metastasis of bladder Cancer cells by maintaining the tumor suppressor genes.
Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3.
Network analyses elucidate the role of SMYD3 in esophageal squamous cell carcinoma.
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.
Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer.
Overexpression of SMYD3 Is Predictive of Unfavorable Prognosis in Hepatocellular Carcinoma.
Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer.
Overexpression of the SMYD3 Promotes Proliferation, Migration, and Invasion of Pancreatic Cancer.
Role of RbBP5 and H3K4me3 in the vicinity of Snail transcription start site during epithelial- mesenchymal- transition in prostate cancer cell.
SET and MYND domain containing protein 3 in cancer.
SETDB-1: A Potential Epigenetic Regulator in Breast Cancer Metastasis.
SMYD2 facilitates cancer cell malignancy and xenograft tumor development through ERBB2-mediated FUT4 expression in colon cancer.
SMYD2 promotes tumorigenesis and metastasis of lung adenocarcinoma through RPS7.
SMYD2 suppresses APC2 expression to activate the Wnt/?-catenin pathway and promotes epithelial-mesenchymal transition in colorectal cancer.
SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma.
SMYD3 promoter hypomethylation is associated with the risk of colorectal cancer.
SMYD3 promotes colon adenocarcinoma (COAD) progression by mediating cell proliferation and apoptosis.
SMYD3 promotes epithelial ovarian cancer metastasis by down-regulating p53 protein stability and promoting p53 ubiquitination.
SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.
SMYD3 promotes the epithelial-mesenchymal transition in breast cancer.
SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration and invasion in esophageal squamous cell carcinoma.
SMYD3 tandem repeats polymorphism is not associated with the occurrence and metastasis of hepatocellular carcinoma in a Chinese population.
Synthesis and biological activity of selenopsammaplin A and its analogues as antitumor agents with DOT1L inhibitory activity.
Synthesis and biological evaluation of benzomorpholine derivatives as novel EZH2 inhibitors for anti-non-small cell lung cancer activity.
Targeting Histone Methyltransferase DOT1L by a Novel Psammaplin A Analog Inhibits Growth and Metastasis of Triple-Negative Breast Cancer.
The role of DOT1L in the proliferation and prognosis of gastric cancer.
Uncommon somatic mutations in metastatic NUT midline carcinoma.
Whole-exome sequencing reveals critical genes underlying metastasis in oesophageal squamous cell carcinoma.
Neoplasms
A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer.
A Case of Acute Myeloid Leukemia with Novel Translocation t(6;11)(p22.2;q23) and Concurrent Insertion ins(11;9)(q23;p21.3p21.3).
A comparative analysis of KMT2D missense variants in Kabuki syndrome, cancers and the general population.
A compass for the cancer journey: scientific, spiritual, and practical directives.
A cytoplasmic COMPASS is necessary for cell survival and triple-negative breast cancer pathogenesis by regulating metabolism.
A knowledge-based framework for the discovery of cancer-predisposing variants using large-scale sequencing breast cancer data.
A Medicinal Chemistry Perspective for Targeting Histone H3 Lysine-79 Methyltransferase DOT1L.
A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response.
A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer.
A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries.
A novel protein expression signature differentiates benign lipomas from well-differentiated liposarcomas.
A novel somatic mutation in ACD induces telomere lengthening and apoptosis resistance in leukemia cells.
A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies.
A Role for PP1/NIPP1 in Steering Migration of Human Cancer Cells.
A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.
A STUDY OF THE RELATIONSHIP BETWEEN LEVELS OF METHYLTRANSFERASES IN PERIPHERAL BLOOD MONONUCLEAR CELLS AND CHARACTERISTICS OF TUMOR IN PATIENTS WITH DUCTAL INVASIVE CARCINOMA OF BREAST.
A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4.
A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers.
A virome-wide clonal integration analysis platform for discovering cancer viral etiology.
Aberrant Activity of Histone-Lysine N-Methyltransferase 2 (KMT2) Complexes in Oncogenesis.
Aberrant expression of SETD1A promotes survival and migration of estrogen receptor ?-positive breast cancer cells.
Aberrant PRDM9 expression impacts the pan-cancer genomic landscape.
Absent, small or homeotic 2-like protein (ASH2L) enhances the transcription of the estrogen receptor ? gene through GATA-binding protein 3 (GATA3).
Adult High Grade B-cell Lymphoma with Burkitt Lymphoma Signature: Genomic features and Potential Therapeutic Targets.
Altered gene expression along the glycolysis-cholesterol synthesis axis is associated with outcome in pancreatic cancer.
Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification.
Amplification of SMYD3 promotes tumorigenicity and intrahepatic metastasis of hepatocellular carcinoma via upregulation of CDK2 and MMP2.
An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation.
An Evolutionarily Conserved Structural Platform for PRC2 Inhibition by a Class of Ezh2 Inhibitors.
An examination of the co-occurrence of modifiable risk factors associated with chronic disease among youth in the COMPASS study.
An Mll4/COMPASS-Lsd1 epigenetic axis governs enhancer function and pluripotency transition in embryonic stem cells.
An organoid-based drug screening identified a menin-MLL inhibitor for endometrial cancer through regulating the HIF pathway.
Analysis of head and neck carcinoma progression reveals novel and relevant stage-specific changes associated with immortalisation and malignancy.
Analysis of SET and MYND Domain-Containing Protein 3 (SMYD3) Expression in Gallbladder Cancer: a Pilot Study.
Analysis of the role of mutations in the KMT2D histone lysine methyltransferase in bladder cancer.
Analysis of the Substrate Specificity of the SMYD2 Protein Lysine Methyltransferase and Discovery of Novel Non-Histone Substrates.
ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma.
Artificial intelligence (AI) and cancer prevention: the potential application of AI in cancer control programming needs to be explored in population laboratories such as COMPASS.
ASH2L drives proliferation and sensitivity to bleomycin and other genotoxins in Hodgkin's lymphoma and testicular cancer cells.
ASH2L is involved in promotion of endometrial cancer progression via upregulation of PAX2 transcription.
Association analysis of KMT2D copy number variation as a positional candidate for growth traits.
Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer.
Association of the variable number of tandem repeats polymorphism in the promoter region of the SMYD3 gene with risk of esophageal squamous cell carcinoma in relation to tobacco smoking.
Authoring experience: the significance and performance of storytelling in Socratic dialogue with rehabilitating cancer patients.
Automated radiation targeting in head-and-neck cancer using region-based texture analysis of PET and CT images.
Automethylation of SUV39H2, an oncogenic histone lysine methyltransferase, regulates its binding affinity to substrate proteins.
Biochemical perspectives on targeting KMT2 methyltransferases in cancer.
Bisphenol A and Phthalates Modulate Peritoneal Macrophage Function in Female Mice Involving SYMD2-H3K36 Dimethylation.
Breast cancer in women with neurofibromatosis type 1 (NF1): a comprehensive case series with molecular insights into its aggressive phenotype.
Burkitt lymphoma in a patient with Kabuki syndrome carrying a novel KMT2D mutation.
C-terminal domain of SMYD3 serves as a unique HSP90-regulated motif in oncogenesis.
C/EBP? enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation.
Cancer Management in Kabuki Syndrome: The First Case of Wilms Tumor and a Literature Review.
Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors.
Care without a compass: Including patients with cancer in COVID-19 studies.
Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors.
CBP mediated DOT1L acetylation confers DOT1L stability and promotes cancer metastasis.
Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer.
Chromatin-regulating proteins as targets for cancer therapy.
Chromosomal abnormalities and molecular landscape of metastasizing mucinous salivary adenocarcinoma.
Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
COMPASS and SWI/SNF complexes in development and disease.
COMPASS Ascending: Emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer.
Comprehensive assessments of germline deletion structural variants reveal the association between prognostic MUC4 and CEP72 deletions and immune response gene expression in colorectal cancer patients.
Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuvant Treatment.
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
Comprehensive genomic profile of cholangiocarcinomas in China.
Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential.
Comprehensive Molecular Characterization of Adamantinoma and OFD-like Adamantinoma Bone Tumors.
Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants.
Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L.
Conservation of epigenetic regulation by the MLL3/4 tumour suppressor in planarian pluripotent stem cells.
Cooperation between SMYD3 and PC4 drives a distinct transcriptional program in cancer cells.
Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer.
Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target.
Corrigendum to "The cancer COMPASS: Navigating the functions of MLL complexes in cancer" [Cancer Genetics 208 (2015) pp. 178-191].
CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade.
Critical roles of SMYD2-mediated ?-catenin methylation for nuclear translocation and activation of Wnt signaling.
Cross-talk between CDK4/6 and SMYD2 regulates gene transcription, tubulin methylation, and ciliogenesis.
Crystal structures of histone and p53 methyltransferase SmyD2 reveal a conformational flexibility of the autoinhibitory C-terminal domain.
Cytogenomic characterization of double minute heterogeneity in therapy related acute myeloid leukemia.
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
Deep Targeted Sequencing and Its Potential Implication for Cancer Therapy in Chinese Patients with Gastric Adenocarcinoma.
Deficiency of H3K79 Histone Methyltransferase Dot1-like Protein (DOT1L) Inhibits Cell Proliferation.
Depletion of H3K79 methyltransferase Dot1L promotes cell invasion and cancer stem-like cell property in ovarian cancer.
Deregulated expression of selected histone methylases and demethylases in prostate carcinoma.
Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors.
Detection of circulating sarcoma tumor cells using a microfluidic chip-type cell sorter.
Detection of gene rearrangements in targeted clinical next-generation sequencing.
Developing the structure of Japan's cancer survivorship guidelines using an expert panel and modified Delphi method.
Development of an eHealth System to Capture and Analyze Patient Sensor and Self-Report Data: Mixed-Methods Assessment of Potential Applications to Improve Cancer Care Delivery.
Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2.
Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3.
Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.
Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening.
Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis.
Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis.
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.
Divergent viral presentation among human tumors and adjacent normal tissues.
Domain swapping and SMYD1 interactions with the PWWP domain of human hepatoma-derived growth factor.
DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression.
Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma.
DOT1L-controlled cell-fate determination and transcription elongation are independent of H3K79 methylation.
DOTting the path to doom: how acceleration of histone methylation leads to leukemia.
Downregulation of MMSET impairs breast cancer proliferation and metastasis through inhibiting Wnt/?-catenin signaling.
DPY30 functions in glucose homeostasis via integrating activated histone epigenetic modifications.
DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells.
Drosophila SETs its Sights on Cancer: Trr/MLL3/4 COMPASS-like complexes in Development and Disease.
Dysregulation of AKT Pathway by SMYD2-Mediated Lysine Methylation on PTEN.
Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry.
Effect of the downregulation of SMYD3 expression by RNAi on RIZ1 expression and proliferation of esophageal squamous cell carcinoma.
Effects of SMYD3 overexpression on transformation, serum dependence, and apoptosis sensitivity in NIH3T3 cells.
Elevated Levels of SET and MYND Domain-Containing Protein 3 Are Correlated with Overexpression of Transforming Growth Factor-?1 in Gastric Cancer.
Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells.
Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma.
Epigenetic modifiers in normal and malignant hematopoiesis.
Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours.
Euchromatic histone lysine methyltransferase 1 regulates cancer development in human gastric cancer by regulating E-cadherin.
Exploration of the Substrate Preference of Lysine Methyltransferase SMYD3 by Molecular Dynamics Simulations.
Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target.
Expression and clinical significance of COMPASS family of histone methyltransferases in clear cell renal cell carcinoma.
Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication.
Expression patterns and the prognostic value of the SMYD family members in human breast carcinoma using integrative bioinformatics analysis.
EZH2 and SMYD3 expression in papillary thyroid cancer.
EZH2 as a potential target in cancer therapy.
FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.
Financial difficulties are associated with greater total pain and suffering among patients with advanced cancer: results from the COMPASS study.
Frameshift mutation of a histone methylation-related gene SETD1B and its regional heterogeneity in gastric and colorectal cancers with high microsatellite instability.
From chromatin to cancer: a new histone lysine methyltransferase enters the mix.
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer.
Genetic and epigenetic changes in fibrosis-associated hepatocarcinogenesis in mice.
Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.
Genome Regulation by Polycomb and Trithorax: 70 Years and Counting.
Genome-scale CRISPR-Cas9 screen of Wnt/?-catenin signaling identifies therapeutic targets for colorectal cancer.
Genome-Wide Analysis of Menin Binding Provides Insights into MEN1 Tumorigenesis.
Genomic analyses of high-grade neuroendocrine gynecological malignancies reveal a unique mutational landscape and therapeutic vulnerabilities.
Genomic Analyses of Metaplastic or Sarcomatoid Carcinomas From Different Organs Revealed Frequent Mutations in KMT2D.
Genomic case report of a low grade bladder tumor metastasis to lung.
Genomic characterization for familial cases with urothelial carcinoma.
Genomic characterization of high-risk non-muscle invasive bladder cancer.
Genomic characterization of metastatic breast cancers.
Genomic characterization of vulvar squamous cell carcinoma.
Genomic profile of breast sarcomas: a comparison with malignant phyllodes tumours.
Genomic Profiling Identified ERCC2 E606Q Mutation in Helicase Domain Respond to Platinum-Based Neoadjuvant Therapy in Urothelial Bladder Cancer.
H3K36 Methylation Antagonizes PRC2-mediated H3K27 Methylation.
High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancer.
High?level SETD1B gene expression is associated with unfavorable prognosis in hepatocellular carcinoma.
Hijacked in cancer: the KMT2 (MLL) family of methyltransferases.
Hijacking a key chromatin modulator creates epigenetic vulnerability for MYC-driven cancer.
Histone 3 lysine-27 demethylase KDM6A coordinates with KMT2B to play an oncogenic role in NSCLC by regulating H3K4me3.
Histone H3 lysine 4 methyltransferase KMT2D.
Histone H3K4 Methyltransferases as Targets for Drug-Resistant Cancers.
Histone lysine methylation and demethylation pathways in cancer.
Histone lysine methyltransferase SET8 is a novel therapeutic target for cancer treatment.
Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression.
Histone methyltransferase ash1l suppresses interleukin-6 production and inflammatory autoimmune diseases by inducing the ubiquitin-editing enzyme a20.
Histone methyltransferase hSETD1A is a Novel Regulator of Metastasis in Breast Cancer.
Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4.
Histone Methyltransferase SETD1A Induces Epithelial-Mesenchymal Transition to Promote Invasion and Metastasis Through Epigenetic Reprogramming of Snail in Gastric Cancer.
Histone methyltransferase SETD1A interacts with HIF1? to enhance glycolysis and promote cancer progression in gastric cancer.
Histone methyltransferase SETD1A participates in lung cancer progression.
Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
Histone methyltransferase SMYD2: ubiquitous regulator of disease.
Histone methyltransferase SMYD3 regulates the expression of transcriptional factors during bovine oocyte maturation and early embryonic development.
Hit identification of SMYD3 enzyme inhibitors using structure-based pharmacophore modeling.
HSF2 regulates aerobic glycolysis by suppression of FBP1 in hepatocellular carcinoma.
Identification of an epigenetic prognostic signature for patients with lower-grade gliomas.
Identification of hub genes and key pathways associated with the progression of gynecological cancer.
Identification of novel EED-EZH2 PPI inhibitors using an in silico fragment mapping method.
IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L.
Impaired recruitment of the histone methyltransferase DOT1L contributes to the incomplete reactivation of tumor suppressor genes upon DNA demethylation.
In Silico/In Vitro Hit-to-Lead Methodology Yields SMYD3 Inhibitor That Eliminates Unrestrained Proliferation of Breast Carcinoma Cells.
In Situ Proteome Profiling and Bioimaging Applications of Small-Molecule Affinity-Based Probes Derived From DOT1L Inhibitors.
Inhibition of DOT1L by Half-Selenopsammaplin A Analogs Suppresses Tumor Growth and EMT-Mediated Metastasis in Triple-Negative Breast Cancer.
Inhibition of Euchromatic Histone Lysine Methyltransferase 2 (EHMT2) Suppresses the Proliferation and Invasion of Cervical Cancer Cells.
Inhibition of histone methyltransferase DOT1L silences ER? gene and blocks proliferation of antiestrogen-resistant breast cancer cells.
Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML.
Inhibition of SMYD2 Sensitized Cisplatin to Resistant Cells in NSCLC Through Activating p53 Pathway.
Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.
Inhibition of the Histone Lysine Methyltransferase EZH2 for the Treatment of Cancer.
Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency.
Integrative molecular characterization of Chinese prostate cancer specimens.
Interaction of BARD1 and HP1 is required for BRCA1 retention at sites of DNA damage.
Involvement of Chromatin Remodeling Genes and the Rho GTPases RhoB and CDC42 in Ovarian Clear Cell Carcinoma.
In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer.
KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas.
KMT2A (MLL)-MLLT1 rearrangement in blastic plasmacytoid dendritic cell neoplasm.
Kmt2a cooperates with menin to suppress tumorigenesis in mouse pancreatic islets.
KMT2A histone methyltransferase contributes to colorectal cancer development by promoting cathepsin Z transcriptional activation.
KMT2A promotes melanoma cell growth by targeting hTERT signaling pathway.
KMT2A regulates cervical cancer cell growth through targeting VDAC1.
KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer.
KMT2C mediates the estrogen dependence of breast cancer through regulation of ER? enhancer function.
Kmt2c mutations enhance HSC self-renewal capacity and convey a selective advantage after chemotherapy.
KMT2C Mutations in Diffuse-Type Gastric Adenocarcinoma Promote Epithelial-to-Mesenchymal Transition.
KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
KMT2D deficiency enhances the anti-cancer activity of L48H37 in pancreatic ductal adenocarcinoma.
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
KMT2D inhibits the growth and metastasis of bladder Cancer cells by maintaining the tumor suppressor genes.
KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.
KMT2D promotes proliferation of gastric cancer cells: evidence from ctDNA sequencing.
KMT2D/MLL2 inactivation is associated with recurrence in adult-type granulosa cell tumors of the ovary.
Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF.
Knockdown of SMYD3 by RNA interference inhibits cervical carcinoma cell growth and invasion in vitro.
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
Look at the compass needle and see your course - navigation as a cancer survivor.
Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3.
Lysine methylation in cancer: SMYD3-MAP3K2 teaches us new lessons in the Ras-ERK pathway.
Lysine methyltransferase 2D regulates pancreatic carcinogenesis through metabolic reprogramming.
Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.
Lysine methyltransferase Smyd2 regulates Hsp90-mediated protection of the sarcomeric titin springs and cardiac function.
m6A modification-mediated CBX8 induction regulates stemness and chemosensitivity of colon cancer via upregulation of LGR5.
Mcm2 deficiency results in short deletions allowing high resolution identification of genes contributing to lymphoblastic lymphoma.
Mechanism of the Conformational Change of the Protein Methyltransferase SMYD3: A Molecular Dynamics Simulation Study.
Merkel Cell Polyomavirus in Merkel Cell Carcinoma: Integration Sites and Involvement of the KMT2D Tumor Suppressor Gene.
Meta-analysis of clinical data using human meiotic genes identifies a novel cohort of highly restricted cancer-specific marker genes.
Methylation of the retinoblastoma tumor suppressor by SMYD2.
MiRNA-217 accelerates the proliferation and migration of bladder cancer via inhibiting KMT2D.
MLL/KMT2A translocations in diffuse large B-cell lymphomas.
MLL3 suppresses tumorigenesis through regulating TNS3 enhancer activity.
MLL3/MLL4/COMPASS Family on Epigenetic Regulation of Enhancer Function and Cancer.
Molecular analysis of encapsulated papillary carcinoma of the breast with and without invasion.
Molecular characterization of an MLL1 fusion and its role in chromosomal instability.
Molecular differences between screen-detected and interval breast cancers are largely explained by PAM50 subtypes.
Multiregional sequence revealed SMARCA4 R1192C mutant clones acquired EGFR C797S mutation in the metastatic site of an EGFR-mutated NSCLC patient.
Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapy.
Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular carcinoma.
Mutational Characterization and Potential Prognostic Biomarkers of Chinese Patients with Esophageal Squamous Cell Carcinoma.
Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center.
Mutational profile of papillary thyroid microcarcinoma with extensive lymph node metastasis.
Network analyses elucidate the role of SMYD3 in esophageal squamous cell carcinoma.
NeuroD1 Dictates Tumor Cell Differentiation in Medulloblastoma.
Neuropathology, cell biology, and newer diagnostic methods.
New open conformation of SMYD3 implicates conformational selection and allostery.
New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse.
Novel germline mutation KMT2A G3131S confers genetic susceptibility to familial myeloproliferative neoplasms.
Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor.
Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells.
NSD2 promotes osteosarcoma cell proliferation and metastasis by inhibiting E-cadherin expression.
Nucleoside and Non-Nucleoside DOT1L Inhibitors: Dawn of MLLrearranged Leukemia.
Oncoproteomic and gene expression analyses identify prognostic biomarkers for second primary malignancy in patients with head and neck squamous cell carcinoma.
Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.
Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous-cell carcinoma.
Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer.
Overexpression of SMYD3 in Ovarian Cancer is Associated with Ovarian Cancer Proliferation and Apoptosis via Methylating H3K4 and H4K20.
Overexpression of SMYD3 Is Predictive of Unfavorable Prognosis in Hepatocellular Carcinoma.
Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer.
Overview on Epigenetic Re-programming: A Potential Therapeutic Intervention in Triple Negative Breast Cancers
Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1-KMT2A-YAP1 and VIM-KMT2A fusions.
PAX3/7-FOXO1 fusion-negative alveolar rhabdomyosarcoma in Schuurs-Hoeijmakers syndrome.
Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK/T-cell lymphoma.
Playing on the Dark Side: SMYD3 Acts as a Cancer Genome Keeper in Gastrointestinal Malignancies.
Primary splenic histiocytic sarcoma associated with hemophagocytic lymphohistiocytosis: A case report and review of literature of next-generation sequencing involving FLT3, NOTCH2, and KMT2A mutations.
Profiles of genomic alterations in primary esophageal follicular dendritic cell sarcoma: A case report.
Prognosis model of colorectal cancer patients based on NOTCH3, KMT2C, and CREBBP mutations.
Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer.
Prognostic significance of stromal SMYD3 expression in colorectal cancer of TNM stage I-III.
Radical resection for cancer of the hypopharynx and cervical oesophagus with repair by stomach transposition.
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation.
Reconstructing the disease model and epigenetic networks for MLL-AF4 leukemia.
Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer.
Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas.
Recurrent Fusions Between YAP1 and KMT2A in Morphologically Distinct Neoplasms Within the Spectrum of Low-grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma.
Recurrent mutations in NF-?B pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas.
Recurrent YAP1 and KMT2A Gene Rearrangements in a Subset of MUC4-negative Sclerosing Epithelioid Fibrosarcoma.
Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
Regulation of the DNA Damage Response and Gene Expression by the Dot1L Histone Methyltransferase and the 53Bp1 Tumour Suppressor.
Repression of p53 activity by Smyd2-mediated methylation.
Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription.
Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy.
Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia.
Restoration of KMT2C/MLL3 in human colorectal cancer cells reinforces genome-wide H3K4me1 profiles and influences cell growth and gene expression.
Reticuloendotheliosis virus strain T induces miR-155 which targets JARID2 and promotes cell survival.
Retinoblastoma Binding Protein 5 Correlates with the Progression in Hepatocellular Carcinoma.
RNA Sequencing of Hepatobiliary Cancer Cell Lines: Data and Applications to Mutational and Transcriptomic Profiling.
Role of somatic cancer mutations in human protein lysine methyltransferases.
SET and MYND domain containing protein 3 in cancer.
SET and MYND domain-containing protein 3 decreases sensitivity to dexamethasone and stimulates cell adhesion and migration in NIH3T3 cells.
SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
SETD1A Promotes Proliferation of Castration-Resistant Prostate Cancer Cells via FOXM1 Transcription.
SETD1A protects from senescence through regulation of the mitotic gene expression program.
SETDB1 promotes gastric carcinogenesis and metastasis via upregulation of CCND1 and MMP9 expression.
Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer.
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery.
Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.
Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation.
SMYD2 facilitates cancer cell malignancy and xenograft tumor development through ERBB2-mediated FUT4 expression in colon cancer.
Smyd2 is a Myc-regulated gene critical for MLL-AF9 induced leukemogenesis.
SMYD2 overexpression is associated with tumor cell proliferation and a worse outcome in human papillomavirus-unrelated nonmultiple head and neck carcinomas.
SMYD2 promotes cervical cancer growth by stimulating cell proliferation.
SMYD2 promotes tumorigenesis and metastasis of lung adenocarcinoma through RPS7.
SMYD2 suppresses APC2 expression to activate the Wnt/?-catenin pathway and promotes epithelial-mesenchymal transition in colorectal cancer.
SMYD2 suppresses p53 activity to promote glucose metabolism in cervical cancer.
SMYD2-dependent HSP90 methylation promotes cancer cell proliferation by regulating the chaperone complex formation.
SMYD3 controls a Wnt-responsive epigenetic switch for ASCL2 activation and cancer stem cell maintenance.
SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.
Smyd3 Is a Transcriptional Potentiator of Multiple Cancer-Promoting Genes and Required for Liver and Colon Cancer Development.
SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.
SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma.
SMYD3 promoter hypomethylation is associated with the risk of colorectal cancer.
SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9.
SMYD3 promotes colon adenocarcinoma (COAD) progression by mediating cell proliferation and apoptosis.
SMYD3 Promotes Homologous Recombination via Regulation of H3K4-mediated Gene Expression.
SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.
SMYD3 promotes the epithelial-mesenchymal transition in breast cancer.
Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation.
SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration and invasion in esophageal squamous cell carcinoma.
SMYD3-associated pathway is involved in the anti-tumor effects of sulforaphane on gastric carcinoma cells.
Smyd3-associated regulatory pathways in cancer.
SMYD3-Mediated H2A.Z.1 Methylation Promotes Cell Cycle and Cancer Proliferation.
SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1.
SMYD3: a regulator of epigenetic and signaling pathways in cancer.
SMYD3: An Oncogenic Driver Targeting Epigenetic Regulation and Signaling Pathways.
Somatic alterations and dysregulation of epigenetic modifiers in cancers.
Somatic cancer mutations in the MLL1 histone methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L complex.
Somatic mutations of DICER1 and KMT2D are frequent in intraocular medulloepitheliomas.
Somatic Mutations of the Mixed-Lineage Leukemia 3 (MLL3) Gene in Primary Breast Cancers.
Spinal ependymoma in a patient with Kabuki syndrome: a case report.
Stable Form of JAB1 Enhances Proliferation and Maintenance of Hematopoietic Progenitors.
Structural Basis for Substrate Preference of SMYD3, A SET Domain-containing Protein Lysine Methyltransferase.
Structural Basis of Substrate Methylation and Inhibition of SMYD2.
Structure of human SMYD2 protein reveals the basis of p53 tumor suppressor methylation.
Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets.
Structure-guided Discovery of a Potent and Selective Cell-active Inhibitor of SETDB1 Tudor Domain.
Studies Identify Non-Hodgkin Lymphoma Suppressor.
Subsequent development of histiocytic sarcoma and follicular lymphoma: cytogenetics and next-generation sequencing analyses provide evidence for transdifferentiation of early common lymphoid precursor-a case report and review of literature.
Synthesis and biological activity of selenopsammaplin A and its analogues as antitumor agents with DOT1L inhibitory activity.
Synthesis and biological evaluation of benzomorpholine derivatives as novel EZH2 inhibitors for anti-non-small cell lung cancer activity.
Synthesis and structure-activity relationship studies of LLY-507 analogues as SMYD2 inhibitors.
Systems biology analysis of hepatitis C virus infection reveals the role of copy number increases in regions of chromosome 1q in hepatocellular carcinoma metabolism.
TALEN-Mediated FLAG-Tagging of Endogenous Histone Methyltransferase DOT1L.
Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets.
Targeted sequencing reveals the somatic mutation landscape in a Swedish breast cancer cohort.
Targeting Histone Methyltransferase DOT1L by a Novel Psammaplin A Analog Inhibits Growth and Metastasis of Triple-Negative Breast Cancer.
Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).
Targeting Smyd3 by next-generation antisense oligonucleotides suppresses liver tumor growth.
Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality.
Targeting the Atf7ip-Setdb1 complex augments antitumor immunity by boosting tumor immunogenicity.
The 11q-Gain/Loss Aberration Occurs Recurrently in MYC-Negative Burkitt-like Lymphoma With 11q Aberration, as Well as MYC-Positive Burkitt Lymphoma and MYC-Positive High-Grade B-Cell Lymphoma, NOS.
The Association of Modifiable Breast Cancer Risk Factors and Somatic Genomic Alterations in Breast Tumors: The Cancer Genome Atlas Network.
The cancer COMPASS: navigating the functions of MLL complexes in cancer.
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
The COMPASS study: A descriptive study on the characteristics of palliative care team consultation for cancer patients in hospitals.
The duality of PRDM proteins: epigenetic and structural perspectives.
The epigenetic factor Kmt2a/Mll1 regulates neural progenitor proliferation and neuronal and glial differentiation.
The evolution of bladder cancer genomics: What have we learned and how can we use it?
The feasibility of a purpose-renewal intervention after treatment for early stage breast cancer: A brief report.
The histone demethylase UTX/KDM6A in cancer: Progress and puzzles.
The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation.
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
The Histone Methyltransferase DOT1L Is a Functional Component of Estrogen Receptor Alpha Signaling in Ovarian Cancer Cells.
The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness.
The histone methyltransferase DOT1L promotes neuroblastoma by regulating gene transcription.
The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target.
The Histone Methyltransferase Smyd2 Is a Negative Regulator of Macrophage Activation by Suppressing Interleukin 6 (IL-6) and Tumor Necrosis Factor ? (TNF-?) Production.
The Histone Methyltransferase SMYD2 Methylates PARP1 and Promotes Poly(ADP-ribosyl)ation Activity in Cancer Cells.
The Lysine Methylase SMYD3 Modulates Mesendodermal Commitment during Development.
The lysine-specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer.
The MLL3/4 H3K4 methyltransferase complex in establishing an active enhancer landscape.
The MLL3/MLL4 branch of the COMPASS family is a major H3K4 monomethylase at enhancers.
The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy.
The role of autophagy in targeted therapy for acute myeloid leukemia.
The role of DOT1L in the proliferation and prognosis of gastric cancer.
The role of histone lysine methyltransferase NSD3 in cancer.
The role of SETD1A and SETD1B in development and disease.
The RS4;11 cell line as a model for leukaemia with t(4;11)(q21;q23): Revised characterisation of cytogenetic features.
The SMYD family proteins in immunology: An update of their obvious and non-obvious relations with the immune system.
The SMYD3 VNTR 3/3 polymorphism confers an increased risk and poor prognosis of hepatocellular carcinoma in a Chinese population.
The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3.
The Trithorax protein Ash1L promotes myoblast fusion by activating Cdon expression.
The upstreams and downstreams of H3K79 methylation by DOT1L.
Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.
Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report.
Transposon mutagenesis identifies cooperating genetic drivers during keratinocyte transformation and cutaneous squamous cell carcinoma progression.
Tubulocystic renal cell carcinoma: a distinct clinicopathologic entity with a characteristic genomic profile.
Tumor haplotype assembly algorithms for cancer genomics.
Tumor slices as a model to evaluate doxorubicin in vitro treatment and expression of trios of genes PRSS11, MTSS1, CLPTM1 and PRSS11, MTSS1, SMYD2 in canine mammary gland cancer.
Two Loops Undergoing Concerted Dynamics Regulate the Activity of the ASH1L Histone Methyltransferase.
Two progressed malignant phyllodes tumors of the breast harbor alterations in genes frequently involved in other advanced cancers.
Uncommon somatic mutations in metastatic NUT midline carcinoma.
Unveiling the Biochemistry of the Epigenetic Regulator SMYD3.
Upregulated expression of G9a is correlated with poor prognosis of gastric cancer patients.
Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy.
Upregulation of histone methyltransferase, DOT1L by matrix hyaluronan promotes MicroRNA-10 expression leading to tumor cell invasion and chemoresistance in cancer stem cells from head and neck squamous cell carcinoma.
Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma.
UTX inhibits EMT-induced breast CSC properties by epigenetic repression of EMT genes in cooperation with LSD1 and HDAC1.
UTX Mutations in Human Cancer.
Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer.
VHL-HIF-2? axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR.
WDR5 supports colon cancer cells by promoting methylation of H3K4 and suppressing DNA damage.
Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified.
Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene.
Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma.
Whole-Exome Sequencing Reveals Frequent Mutations in Chromatin Remodeling Genes in Mammary and Extramammary Paget's Diseases.
XIST lost induces ovarian cancer stem cells to acquire taxol resistance via a KMT2C-dependent way.
[An Analysis of contributions to the main German chat forum for cancer patients regarding palliative care].
[Experimental research of therapeutic effect on hepatocellular carcinoma of targeting SMYD3 gene inhibition by RNA interference]
Neoplastic Cells, Circulating
SETD1A protects from senescence through regulation of the mitotic gene expression program.
Nervous System Diseases
ODLURO syndrome: personal experience and review of the literature.
The role of SETD1A and SETD1B in development and disease.
Neuralgia
HPV vaccination syndrome. A questionnaire-based study.
N6-Methyladenosine Demethylase FTO Contributes to Neuropathic Pain by Stabilizing G9a Expression in Primary Sensory Neurons.
Neuroblastoma
Fgfr3 is a transcriptional target of Ap2delta and Ash2l-containing histone methyltransferase complexes.
The histone methyltransferase DOT1L promotes neuroblastoma by regulating gene transcription.
Transcriptional Changes following Cellular Knockdown of the Schizophrenia Risk Gene SETD1A Are Enriched for Common Variant Association with the Disorder.
Neurocytoma
Neuropathology, cell biology, and newer diagnostic methods.
Neurodegenerative Diseases
Polymorphism distribution of prion protein codon 117, 129 and 171 in Taiwan.
Neuroectodermal Tumors, Primitive
Somatic mutations of DICER1 and KMT2D are frequent in intraocular medulloepitheliomas.
Neuroendocrine Tumors
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
Neurologic Manifestations
Refractory celiac disease type II: An atypical case highlighting limitations of the current classification system.
Obesity
A de novo KMT2D mutation in a girl with Kabuki syndrome associated with endocrine symptoms: a case report.
Are School Substance Use Policy Violation Disciplinary Consequences Associated with Student Engagement in Cannabis?
Changing social inequalities in smoking, obesity and cause-specific mortality: Cross-national comparisons using compass typology.
Clustering of risk-related modifiable behaviours and their association with overweight and obesity among a large sample of youth in the COMPASS study.
Dot1l interacts with Zc3h10 to activate Ucp1 and other thermogenic genes.
DOT1L Regulates Thermogenic Adipocyte Differentiation and Function via Modulating H3K79 Methylation.
Evaluating the Impact of the Healthy Kids Community Challenge (HKCC) on Physical Activity of Older Youth.
Evaluation of BMI-based classification of adolescent overweight and obesity: choice of percentage body fat cutoffs exerts a large influence. The COMPASS study.
High School Intramural Participation and Substance Use: A Longitudinal Analysis of COMPASS Data.
Problem Video Gaming Among Children Enrolled in Tertiary Weight Management Programs.
Reluctancy towards Help-Seeking for Mental Health Concerns at Secondary School among Students in the COMPASS Study.
The Combating Obesity in M?ori and Pasifika Adolescent School-Children Study: COMPASS Methodology and Study Protocol.
Why Obesity?
Obesity, Morbid
Electronic Gaming Characteristics Associated with Class 3 Severe Obesity in Youth Who Attend the Pediatric Weight Management Programs of the COMPASS Network.
Pilot Testing of a Patient Decision Aid for Adolescents with Severe Obesity in US Pediatric Weight Management Programs within the COMPASS Network.
Oligospermia
Meiotic epigenetic factor PRDM9 impacts sperm quality of hybrid mice.
Prdm9 incompatibility controls oligospermia and delayed fertility but no selfish transmission in mouse intersubspecific hybrids.
Optic Nerve Diseases
A Comparison between the Compass Fundus Perimeter and the Humphrey Field Analyzer.
Orthostatic Intolerance
Association between autonomic dysfunction and fatigue in Parkinson disease.
Children with Functional Nausea-Comorbidities outside the Gastrointestinal Tract.
Clinical Assessment of Autonomic Function in Fibromyalgia by the Refined and Abbreviated Composite Autonomic Symptom Score (COMPASS 31): A Case-Controlled Study.
Prevalence and characteristics of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in Poland: a cross-sectional study.
The composite autonomic symptom scale 31 is a useful screening tool for patients with Parkinsonism.
Time Course of Autonomic Symptoms in Postural Orthostatic Tachycardia Syndrome (POTS) Patients: Two-Year Follow-Up Results.
Translation and linguistic validation of the Composite Autonomic Symptom Score COMPASS 31.
Osteoarthritis
DOT1L safeguards cartilage homeostasis and protects against osteoarthritis.
Increased susceptibility to develop spontaneous and post-traumatic osteoarthritis in Dot1l-deficient mice.
Osteoarthritis year 2013 in review: genetics and genomics.
Review Article: Is Wnt Signaling an Attractive Target for the Treatment of Osteoarthritis?
The DOT1L rs12982744 polymorphism is associated with osteoarthritis of the hip with genome-wide statistical significance in males.
To Wnt or not to Wnt: the bone and joint health dilemma.
Osteoarthritis, Hip
Genome-wide association and functional studies identify the DOT1L gene to be involved in cartilage thickness and hip osteoarthritis.
The DOT1L rs12982744 polymorphism is associated with osteoarthritis of the hip with genome-wide statistical significance in males.
Osteoarthritis, Knee
Analysis of Polymorphisms in the MATN3 and DOT1L Genes and CTX-II Urinary Levels in Patients with Knee Osteoarthritis in a Northeast Mexican-Mestizo Population.
Association Between Single Nucleotide Polymorphisms of DOT1L Gene and Risk of Knee Osteoarthritis in a Chinese Han Population.
Osteoporosis
Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women.
The histone methyltransferase DOT1L inhibits osteoclastogenesis and protects against osteoporosis.
Osteosarcoma
KMT2C modulates migration and invasion processes in osteosarcoma cell lines.
The nuclear-cytoplasmic trafficking of a chromatin-modifying and remodelling protein (KMT2C), in osteosarcoma.
Whole-exome analysis in osteosarcoma to identify a personalized therapy.
Ovarian Neoplasms
Depletion of H3K79 methyltransferase Dot1L promotes cell invasion and cancer stem-like cell property in ovarian cancer.
Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis.
Overexpression of SMYD3 in Ovarian Cancer is Associated with Ovarian Cancer Proliferation and Apoptosis via Methylating H3K4 and H4K20.
Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer.
SET and MYND Domain-Containing Protein 3 (SMYD3) Polymorphism as a Risk Factor for Susceptibility and Poor Prognosis in Ovarian Cancer.
SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.
The Histone Methyltransferase DOT1L Is a Functional Component of Estrogen Receptor Alpha Signaling in Ovarian Cancer Cells.
XIST lost induces ovarian cancer stem cells to acquire taxol resistance via a KMT2C-dependent way.
Overweight
Clustering of risk-related modifiable behaviours and their association with overweight and obesity among a large sample of youth in the COMPASS study.
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.
Pancreatic Diseases
Biomarkers in the Differential Diagnosis of Pancreatic Diseases: Looking for a Compass.
Pancreatic Neoplasms
Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer.
Copy number variation and cytidine analogue cytotoxicity: a genome-wide association approach.
Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target.
Genomic and Epigenomic Landscaping Defines New Therapeutic Targets for Adenosquamous Carcinoma of the Pancreas.
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial.
Lysine methyltransferase 2D regulates pancreatic carcinogenesis through metabolic reprogramming.
Overexpression of the SMYD3 Promotes Proliferation, Migration, and Invasion of Pancreatic Cancer.
Pancreatic cancer: The COMPASS shows the way.
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Smyd3-associated regulatory pathways in cancer.
The pancreatic cancer genome revisited.
Pancytopenia
Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation.
Paralysis
Posterior interosseous nerve palsy following placement of the compass elbow hinge for acute instability: a case report.
Paraproteinemias
DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.
Parkinsonian Disorders
Parkinsonism and Positive Dopamine Transporter Imaging in a Patient with a Novel KMT2B Variant.
The composite autonomic symptom scale 31 is a useful screening tool for patients with Parkinsonism.
Pediatric Obesity
Evaluation of BMI-based classification of adolescent overweight and obesity: choice of percentage body fat cutoffs exerts a large influence. The COMPASS study.
Perinatal Death
Increased susceptibility to develop spontaneous and post-traumatic osteoarthritis in Dot1l-deficient mice.
Loss of SMYD1 Results in Perinatal Lethality via Selective Defects within Myotonic Muscle Descendants.
Peripheral Arterial Disease
A COMPASS for VOYAGERs with revascularized peripheral artery disease.
Anticoagulation in Atherosclerotic Disease.
Anticoagulation in Patients with Ischaemic Heart Disease and Peripheral Arterial Disease: Clinical Implications of COMPASS Study.
Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry.
Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial.
Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective.
Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
External applicability of the COMPASS trial: the Western Denmark Heart Registry.
Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease.
How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.
Major Adverse Limb Events in Lower Extremity Peripheral Artery Disease: COMPASS Trial.
Medical management of stable peripheral artery disease: the COMPASS trial. Perspectives from a vascular standpoint.
Patients with Peripheral Artery Disease in the COMPASS Trial.
Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial.
Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial.
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.
Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease.
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial.
Rivaroxaban versus Clopidogrel for Peripheral Artery Disease: A Clinico-Economic Approach of the COMPASS trial.
Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.
Role of rivaroxaban in the prevention of atherosclerotic events.
Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy.
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
[Dual Pathway Inhibition in Atherosclerosis - Which Patients Benefit?]
[New possibilities of antithrombotic therapy improving prognosis in patients with stenosing atherosclerosis of carotid arteries].
Peripheral Nervous System Diseases
The Autonomic Symptom Profile: a new instrument to assess autonomic symptoms.
Peritoneal Fibrosis
Inhibition of the H3K4 methyltransferase SET7/9 ameliorates peritoneal fibrosis.
Pheochromocytoma
Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene.
Photosensitivity Disorders
Benign summer light eruption and polymorphic light eruption: genetic and functional studies suggest that a revised nomenclature is required.
Phyllodes Tumor
Genomic landscapes of breast fibroepithelial tumors.
Malignant phyllodes tumour of the breast mimicking endometriosis.
Pneumonia
The Methyltransferase DOT1L Controls Activation and Lineage Integrity in CD4+ T Cells during Infection and Inflammation.
Pneumothorax
Surgical management of pneumothorax: still sailing with no compass.
Poliomyelitis
Poliomyelitis surveillance: the compass for eradication.
Polycystic Kidney Diseases
Cross-talk between CDK4/6 and SMYD2 regulates gene transcription, tubulin methylation, and ciliogenesis.
Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.
Polycystic kidney disease: SMYD2 is a novel epigenetic regulator of cyst growth.
Polycystic Kidney, Autosomal Dominant
Cross-talk between CDK4/6 and SMYD2 regulates gene transcription, tubulin methylation, and ciliogenesis.
Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.
Polydactyly
Corrigendum to "Preaxial polydactyly in an individual with Wiedemann-Steiner syndrome caused by a novel nonsense mutation in KMT2A. Am J Med Genet Part A. 2017;173A:2821-2,825".
Preaxial polydactyly in an individual with Wiedemann-Steiner syndrome caused by a novel nonsense mutation in KMT2A.
Polyuria
Aqp5 is a new transcriptional target of Dot1a and a regulator of Aqp2.
Prader-Willi Syndrome
Epigenetics meets GPCR: inhibition of histone H3 methyltransferase (G9a) and histamine H3 receptor for Prader-Willi Syndrome.
Pre-Eclampsia
Advocacy organisations as partners in pre-eclampsia progress: patient involvement improves outcomes.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A lineage switch from NPM1-mutant acute myeloid leukemia to acute T-cell lymphoblastic leukemia with KMT2D and ARID2 mutant.
A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial.
Acute lymphoblastic leukemia in infants: a quarter century of nationwide efforts in Japan.
Azacitidine successfully maintained the second remission in an infant with KMT2A-rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation.
B-cell lymphoblastic lymphoma with cutaneous involvement and a KMT2A gene rearrangement.
Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol.
DNA methylation profiling of pediatric B-cell lymphoblastic leukemia with KMT2A rearrangement identifies hypomethylation at enhancer sites.
First case of B ALL with KMT2A-MAML2 rearrangement: a case report.
Flow cytometric predictive scoring systems for common fusions ETV6/RUNX1, BCR/ABL1, TCF3/PBX1 and rearrangements of the KMT2A gene, proposed for the initial cytogenetic approach in cases of B-acute lymphoblastic leukemia.
Genetic mutational analysis of pediatric acute lymphoblastic leukemia from a single center in China using exon sequencing.
Hematopoietic stem cell transplantation for infants with high-risk KMT2A gene rearranged acute lymphoblastic leukemia.
Inv(11)(q21q23); KMT2A-MAML2, a Recurrent Genetic Abnormality in T-Cell Therapy-related Acute Lymphoblastic Leukemia.
Is acute lymphoblastic leukemia with mature B-cell phenotype and KMT2A rearrangements a new entity? A systematic review and meta-analysis.
Molecular characterization of KMT2A fusion partner genes in 13 cases of pediatric leukemia with complex or cryptic karyotypes.
Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study.
Outcomes of Acute Lymphoblastic Leukemia with KMT2A (MLL) rearrangement - The MD Anderson Experience.
SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor.
Whole transcriptome sequencing reveals a KMT2A-USP2 fusion in infant acute myeloid leukemia.
Whole-exome sequencing of a rare case of familial childhood acute lymphoblastic leukemia reveals putative predisposing mutations in Fanconi anemia genes.
XRCC4 rs28360071 intronic variant is associated with increased risk for infant acute lymphoblastic leukemia with KMT2A rearrangements.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia.
Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.
Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.
RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia.
The lysine methyltransferase SMYD2 is required for normal lymphocyte development and survival of hematopoietic leukemias.
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.
Primary Dysautonomias
Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjogren's syndrome.
HPV vaccination syndrome. A questionnaire-based study.
Prion Diseases
Polymorphism distribution of prion protein codon 117, 129 and 171 in Taiwan.
Progeria
The Role of Dot1l in Prenatal and Postnatal Murine Chondrocytes and Trabecular Bone.
Prostatic Neoplasms
DOT1L in prostate cancer.
High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.
Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer.
Integrated Analysis of Genetic Abnormalities of the Histone Lysine Methyltransferases in Prostate Cancer.
KAT8 Regulates Androgen Signaling in Prostate Cancer Cells.
Long and noncoding RNAs (lnc-RNAs) determine androgen receptor dependent gene expression in prostate cancer growth in vivo.
Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3.
Mutational and transcriptomic landscapes of a rare human prostate basal cell carcinoma.
Role of RbBP5 and H3K4me3 in the vicinity of Snail transcription start site during epithelial- mesenchymal- transition in prostate cancer cell.
SETD1A Promotes Proliferation of Castration-Resistant Prostate Cancer Cells via FOXM1 Transcription.
Small molecule inhibitors of the prostate cancer target KMT2D.
SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription.
SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.
The COMPASs Study: Community Preferences for Prostate cAncer Screening. Protocol for a quantitative preference study.
Three-dimensional dose reconstruction-based pretreatment dosimetric verification in volumetric modulated arc therapy for prostate cancer.
Transcriptional regulation of 15-lipoxygenase expression by histone h3 lysine 4 methylation/demethylation.
Prurigo
Benign summer light eruption and polymorphic light eruption: genetic and functional studies suggest that a revised nomenclature is required.
Pruritus
[Pruritus. Physiopathology, clinical features, and treatment]
Psoriasis
Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis.
Psychomotor Agitation
Navigation.
Pterygium
Comparison of Different Measurement Tools and Dimensional Parameters of Pterygium to Investigate its Impact on Refractive Indices and Ocular Aberrations.
Pulmonary Arterial Hypertension
Navigating the uncharted waters of combination therapy in pulmonary arterial hypertension: COMPASS or dead-reckoning.
Pulmonary Disease, Chronic Obstructive
Investigation of the Clinical, Radiological and Biological Factors Associated with Disease Progression, Phenotypes and Endotypes of COPD in China (COMPASS): study design, protocol and rationale.
SMYD3 promotes colon adenocarcinoma (COAD) progression by mediating cell proliferation and apoptosis.
[Health and disease in the Netherlands: the Dutch National Public Health Compass as a source of information]
Pulpitis
ASH1L Suppresses Matrix Metalloproteinase through Mitogen-activated Protein Kinase Signaling Pathway in Pulpitis.
Renal Insufficiency
Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry.
Retinoblastoma
Crystal structures of histone and p53 methyltransferase SmyD2 reveal a conformational flexibility of the autoinhibitory C-terminal domain.
Effect of the downregulation of SMYD3 expression by RNAi on RIZ1 expression and proliferation of esophageal squamous cell carcinoma.
Lysine methyltransferase Smyd2 regulates Hsp90-mediated protection of the sarcomeric titin springs and cardiac function.
Methylation of the retinoblastoma tumor suppressor by SMYD2.
Rhabdomyosarcoma
Smyd1 And G6Pd Modulation Are Critical Events For Mir-206-Mediated Differentiation Of Rhabdomyosarcoma.
Rheumatic Diseases
[Back to school physical education despite rheumatism : Development and testing of a sport scientific-based physical education certification].
Rubinstein-Taybi Syndrome
KMT2C/D COMPASS complex-associated diseases [KCDCOM-ADs]: an emerging class of congenital regulopathies.
Sarcoma
First case of B ALL with KMT2A-MAML2 rearrangement: a case report.
KMT2A (MLL) fusions in aggressive sarcomas in young adults.
Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1-KMT2A-YAP1 and VIM-KMT2A fusions.
Recurrent Fusions Between YAP1 and KMT2A in Morphologically Distinct Neoplasms Within the Spectrum of Low-grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma.
Sarcoma, Myeloid
Clinicopathological characteristics of de novo and secondary myeloid sarcoma: a monocentric retrospective study.
Mutations within the Activation Loop Domain of FLT3 in Two Pediatric Patients with Refractory Infant Acute Myeloid Leukemia.
Myeloid Sarcoma of the Testis in Children: Clinicopathologic and Immunohistochemical Characteristics With KMT2A (MLL) Gene Rearrangement Correlation.
Rare myeloid sarcoma with KMT2A (MLL)-ELL fusion presenting as a vaginal wall mass.
Scoliosis
De novo loss-of-function variants of ASH1L are associated with an emergent neurodevelopmental disorder.
Seizures
A novel de novo frameshift variant in SETD1B causes epilepsy.
ASH1L mutation caused seizures and intellectual disability in twin sisters.
Clinical Characteristics and Genotype-Phenotype Correlation in Children with KMT2E Gene-Related Neurodevelopmental Disorders: Report of Two New Cases and Review of Published Literature.
Delineating the molecular and phenotypic spectrum of the SETD1B-related syndrome.
Novel KMT2B mutation causes cerebellar ataxia: Expanding the clinical phenotype.
SETD1B-associated neurodevelopmental disorder.
Sepsis
Histone methyltransferase ash1l suppresses interleukin-6 production and inflammatory autoimmune diseases by inducing the ubiquitin-editing enzyme a20.
Shock, Septic
Bioinformatics Analysis of Gene Expression Profiles for Risk Prediction in Patients with Septic Shock.
Skin Neoplasms
Exome sequencing identifies novel mutation signatures of UV radiation and trichostatin A in primary human keratinocytes.
Sleep Apnea Syndromes
De novo loss-of-function variants of ASH1L are associated with an emergent neurodevelopmental disorder.
Sleep Deprivation
Modifiable predictors of insufficient sleep durations: A longitudinal analysis of youth in the COMPASS study.
Small Cell Lung Carcinoma
KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer.
Smoldering Multiple Myeloma
DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.
Sotos Syndrome
Growth disrupting mutations in epigenetic regulatory molecules are associated with abnormalities of epigenetic aging.
Spondylitis
Biomechanical assessment of balance and posture in subjects with inclosing spondylitis.
Squamous Cell Carcinoma of Head and Neck
SMYD2 overexpression is associated with tumor cell proliferation and a worse outcome in human papillomavirus-unrelated nonmultiple head and neck carcinomas.
The non-coding landscape of head and neck squamous cell carcinoma.
Upregulation of histone methyltransferase, DOT1L by matrix hyaluronan promotes MicroRNA-10 expression leading to tumor cell invasion and chemoresistance in cancer stem cells from head and neck squamous cell carcinoma.
Stevens-Johnson Syndrome
Using a claims database to investigate drug-induced Stevens-Johnson syndrome.
Stomach Neoplasms
ATM Signaling Pathway Is Implicated in the SMYD3-mediated Proliferation and Migration of Gastric Cancer Cells.
Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trial.
Difference of molecular alterations in HER2-positive and HER2-negative gastric cancers by whole-genome sequencing analysis.
Downregulation of KMT2D suppresses proliferation and induces apoptosis of gastric cancer.
Euchromatic histone lysine methyltransferase 1 regulates cancer development in human gastric cancer by regulating E-cadherin.
Exome sequencing reveals three novel candidate predisposition genes for diffuse gastric cancer.
Expression of Concern: The role of DOT1L in the proliferation and prognosis of gastric cancer.
Genetic predisposition to gastric cancer.
Genomic alterations in advanced gastric cancer endoscopic biopsy samples using targeted next-generation sequencing.
Hesperetin promotes DOT1L degradation and reduces histone H3K79 methylation to inhibit gastric cancer metastasis.
Histone Methyltransferase SETD1A Induces Epithelial-Mesenchymal Transition to Promote Invasion and Metastasis Through Epigenetic Reprogramming of Snail in Gastric Cancer.
Histone methyltransferase SETD1A interacts with HIF1? to enhance glycolysis and promote cancer progression in gastric cancer.
Increased expression of EHMT2 associated with H3K9me2 level contributes to the poor prognosis of gastric cancer.
Induction of a Pathological Complete Response by Four Courses of Neoadjuvant Chemotherapy for Gastric Cancer: Early Results of the Randomized Phase II COMPASS Trial.
KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.
KMT2D promotes proliferation of gastric cancer cells: evidence from ctDNA sequencing.
miRNA-584-3p inhibits gastric cancer progression by repressing Yin Yang 1- facilitated MMP-14 expression.
Overexpression of SMYD2 contributes to malignant outcome in gastric cancer.
Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer.
Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer.
The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors.
The role of DOT1L in the proliferation and prognosis of gastric cancer.
Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy.
Stroke
A Person-Centered Approach to Poststroke Care: The COMprehensive Post-Acute Stroke Services Model.
Beat-by-Beat Estimation of the Left Ventricular Pressure-Volume Loop Under Clinical Conditions.
COMPASS Trial in Transitional Stroke Care: Navigating Towards True North.
COMPASS-CP: An Electronic Application to Capture Patient-Reported Outcomes to Develop Actionable Stroke and Transient Ischemic Attack Care Plans.
Democratizing health system data to impact social and environmental health contexts: a novel collaborative community data-sharing model.
Development of a computerised decision aid for thrombolysis in acute stroke care.
Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry.
Ensuring respect for persons in COMPASS: a cluster randomised pragmatic clinical trial.
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
External applicability of the COMPASS trial: the Western Denmark Heart Registry.
Genome-Wide Association Study Meta-Analysis of Stroke in 22 000 Individuals of African Descent Identifies Novel Associations With Stroke.
Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease.
Hospital recruitment for a pragmatic cluster-randomized clinical trial: Lessons learned from the COMPASS study.
Hospital to Home Transition for Patients With Stroke Under Bundled Payments.
How engagement of a diverse set of stakeholders shaped the design, implementation, and dissemination of a multicenter pragmatic trial of stroke transitional care: The COMPASS study.
Implementation of a billable transitional care model for stroke patients: the COMPASS study.
Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial.
Meta-Analysis of Genome-Wide Association Studies Identifies Genetic Risk Factors for Stroke in African Americans.
Methods guiding stakeholder engagement in planning a pragmatic study on changing stroke systems of care.
Non-vitamin K antagonist oral anticoagulants (NOACs) in the treatment of coronary and peripheral atherosclerosis. Expert Consensus.
Novel Oral Anticoagulants in Peripheral Artery Disease. Current Evidence.
Patient Factors Associated With Attendance at a Comprehensive Postacute Stroke Visit: Insight From the Vanguard Site.
Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines.
Randomized Pragmatic Trial of Stroke Transitional Care: The COMPASS Study.
Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial.
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy.
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study.
Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD.
Stroke Outcomes in the COMPASS Trial.
The COMPASS trial: practical considerations for application after coronary artery bypass surgery.
The Cost of Implementing and Sustaining the COMprehensive Post-Acute Stroke Services Model.
Usefulness of Coronary Artery Calcium to Identify Adults of Sufficiently High Risk for Atherothrombotic Cardiovascular Events to Consider Low-Dose Rivaroxaban Thromboprophylaxis (from MESA).
[Atherosclerotic Cardiovascular Diseases and Type 2 Diabetes Mellitus - new Developments in the Treatment].
[Combined Antithrombotic Therapy in Patients with a Stable Atherosclerotic Cardiovascular Diseases: What Direction did COMPASS Show?]
[Current opportunities for secondary prevention of atherothrombotic stroke].
[Health and disease in the Netherlands: the Dutch National Public Health Compass as a source of information]
[New possibilities of antithrombotic therapy improving prognosis in patients with stenosing atherosclerosis of carotid arteries].
Tachycardia, Ventricular
[Is programmed ventricular stimulation still up to date in the medicinal evaluation of ventricular tachycardia?]
Testicular Neoplasms
ASH2L drives proliferation and sensitivity to bleomycin and other genotoxins in Hodgkin's lymphoma and testicular cancer cells.
Correction to: ASH2L drives proliferation and sensitivity to bleomycin and other genotoxins in Hodgkin's lymphoma and testicular cancer cells.
Thrombosis
European Society of Cardiology (ESC) Annual Congress Report From Barcelona 2017.
The COMPASS trial: practical considerations for application after coronary artery bypass surgery.
[Current opportunities for secondary prevention of atherothrombotic stroke].
[New possibilities of antithrombotic therapy improving prognosis in patients with stenosing atherosclerosis of carotid arteries].
Thymoma
Pan-Cancer Landscape Analysis Reveals Recurrent KMT2A-MAML2 Gene Fusion in Aggressive Histologic Subtypes of Thymoma.
Thymic adenocarcinoma accompanied by type A thymoma and pulmonary minimally invasive adenocarcinoma and harboring distinct gene alterations: A case report.
Thyroid Cancer, Papillary
EZH2 and SMYD3 expression in papillary thyroid cancer.
Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.
Thyroid Carcinoma, Anaplastic
Novel role of ASH1L histone methyltransferase in anaplastic thyroid carcinoma.
Thyroid Neoplasms
Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours.
EZH2 and SMYD3 expression in papillary thyroid cancer.
Novel role of ASH1L histone methyltransferase in anaplastic thyroid carcinoma.
Tooth Attrition
Individual tooth macrowear pattern guides the reconstruction of Sts 52 (Australopithecus africanus) dental arches.
Tooth Loss
Dental arch perimeter changes as a result from premature loss of primary anterior teeth due to trauma: A case series in infant and pre-school children.
Tourette Syndrome
Mutations in ASH1L confer susceptibility to Tourette syndrome.
Role of Ash1l in Tourette syndrome and other neurodevelopmental disorders.
Spontaneous hyperactivity in Ash1l mutant mice, a new model for Tourette syndrome.
Triple Negative Breast Neoplasms
A cytoplasmic COMPASS is necessary for cell survival and triple-negative breast cancer pathogenesis by regulating metabolism.
Aberrant expression of SETD1A promotes survival and migration of estrogen receptor ?-positive breast cancer cells.
Dysregulation of non-histone molecule miR205 and LRG1 post-transcriptional de-regulation by SETD1A in triple negative breast cancer.
Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.
Inhibition of DOT1L by Half-Selenopsammaplin A Analogs Suppresses Tumor Growth and EMT-Mediated Metastasis in Triple-Negative Breast Cancer.
Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.
Targeting Histone Methyltransferase DOT1L by a Novel Psammaplin A Analog Inhibits Growth and Metastasis of Triple-Negative Breast Cancer.
Ureteral Obstruction
Blocking the histone lysine 79 methyltransferase DOT1L alleviates renal fibrosis through inhibition of renal fibroblast activation and epithelial-mesenchymal transition.
Critical roles of SMYD2 lysine methyltransferase in mediating renal fibroblast activation and kidney fibrosis.
Urinary Bladder Neoplasms
A virome-wide clonal integration analysis platform for discovering cancer viral etiology.
Analysis of the role of mutations in the KMT2D histone lysine methyltransferase in bladder cancer.
Effect of SMYD3 on biological behavior and H3K4 methylation in bladder cancer.
High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancer.
KMT2D inhibits the growth and metastasis of bladder Cancer cells by maintaining the tumor suppressor genes.
MiRNA-217 accelerates the proliferation and migration of bladder cancer via inhibiting KMT2D.
The BBN model: a mouse bladder cancer model featuring basal-subtype gene expression and MLL3/MLL4 genetic disruption.
The lysine-specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer.
Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy.
Uterine Cervical Neoplasms
Inhibition of Euchromatic Histone Lysine Methyltransferase 2 (EHMT2) Suppresses the Proliferation and Invasion of Cervical Cancer Cells.
KMT2A regulates cervical cancer cell growth through targeting VDAC1.
Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
SMYD2 promotes cervical cancer growth by stimulating cell proliferation.
SMYD2 suppresses p53 activity to promote glucose metabolism in cervical cancer.
Vascular Diseases
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?
Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients.
COMPASS for Vascular Surgeons: Practical Considerations.
Correction to: The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease.
Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System.
Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context.
Nullifying epigenetic writer DOT1L attenuates neointimal hyperplasia.
Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios.
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy.
Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease.
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial.
Rivaroxaban: searching the integral vascular protection.
The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease.
Vascular disease: Reduction in major adverse limb events in the COMPASS trial.
[Mortality benefit with different antithrombotic therapies in patients with stable vascular disease: from pathophysiology to the clinical impact in the real world. The COMPASS study].
Vesicular Stomatitis
Interferon-? Stimulation Elicited by the Influenza Virus Is Regulated by the Histone Methylase Dot1L through the RIG-I-TRIM25 Signaling Axis.
The DOT1L inhibitor Pinometostat decreases the host-response against infections: Considerations about its use in human therapy.
Virus Diseases
A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells.
Epigenetic control of Foxp3 by SMYD3 H3K4 histone methyltransferase controls iTreg development and regulates pathogenic T-cell responses during pulmonary viral infection.
Human papillomavirus and the landscape of secondary genetic alterations in oral cancers.
Interferon-? Stimulation Elicited by the Influenza Virus Is Regulated by the Histone Methylase Dot1L through the RIG-I-TRIM25 Signaling Axis.
Methyltransferase Dot1l preferentially promotes innate IL-6 and IFN-? production by mediating H3K79me2/3 methylation in macrophages.
Notch ligand Delta-like 4 induces epigenetic regulation of Treg cell differentiation and function in viral infection.
Quantitative Proteomic Discovery of Dynamic Epigenome Changes that Control Human Cytomegalovirus (HCMV) Infection.
Waardenburg Syndrome
Triple diagnosis of Wiedemann-Steiner, Waardenburg and DLG3-related intellectual disability association found by WES: A case report.
Williams Syndrome
Evaluation of PRDM9 variation as a risk factor for recurrent genomic disorders and chromosomal non-disjunction.
Wolf-Hirschhorn Syndrome
A Scalable Platform for Producing Recombinant Nucleosomes with Codified Histone Methyltransferase Substrate Preferences.
Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway.
[histone h3]-lysine4 n-trimethyltransferase deficiency
Aqp5 is a new transcriptional target of Dot1a and a regulator of Aqp2.
Ash1l controls quiescence and self-renewal potential in hematopoietic stem cells.
CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade.
Deficiency of H3K79 Histone Methyltransferase Dot1-like Protein (DOT1L) Inhibits Cell Proliferation.
Differentiation and localization of interneurons in the developing spinal cord depends on DOT1L expression.
Dot1l deficiency leads to increased intercalated cells and upregulation of V-ATPase B1 in mice.
Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma.
ES cell cycle progression and differentiation require the action of the histone methyltransferase Dot1L.
Histone H3 lysine K4 methylation and its role in learning and memory.
KMT2D deficiency enhances the anti-cancer activity of L48H37 in pancreatic ductal adenocarcinoma.
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.
Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.
Setd1a and NURF mediate chromatin dynamics and gene regulation during erythroid lineage commitment and differentiation.
SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Setd1a regulates progenitor B-cell-to-precursor B-cell development through histone H3 lysine 4 trimethylation and Ig heavy-chain rearrangement.
Setd1b, encoding a histone 3 lysine 4 methyltransferase, is a maternal effect gene required for the oogenic gene expression program.
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
The selective activation of p53 target genes regulated by SMYD2 in BIX-01294 induced autophagy-related cell death.